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Neuroblastoma is the most common extra-cranial solid tumor of childhood. Despite signifi-
cant advances, it currently still remains one of the most difficult childhood cancers to cure,
with less than 40% of patients with high-risk disease being long-term survivors. MYCN is
a proto-oncogene implicated to be directly involved in neuroblastoma development. Ampli-
fication of MYCN is associated with rapid tumor progression and poor prognosis. Novel
therapeutic strategies which can improve the survival rates whilst reducing the toxicity
in these patients are therefore required. Here we discuss genes regulated by MYCN in
neuroblastoma, with particular reference to p53, SKP2, and DKK3 and strategies that may
be employed to target them.
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INTRODUCTION
Neuroblastoma, an embryonal malignancy of the developing
neural crest, is the most common extra-cranial solid tumor of
childhood. It accounts for 8–10% of all pediatric cancers and 15%
of childhood cancer mortality (Park et al., 2010). Over 50% of
patients present with high-risk metastatic disease at the time of
diagnosis and most will respond to intensive multi-modal therapy
despite significant acute toxicities. However relapse with chemore-
sistant disease is common and the overall long-term survival of
high-risk patients currently remains less than 40%, with those that
survive often having long-term toxicities. Thus there is a continu-
ing need to identify novel, less toxic therapies that will ultimately
improve the survival of this subset of patients. A typical feature of
high-risk disease is MYCN amplification which occurs in ∼25%
of neuroblastoma, associating with rapid tumor progression and
a poor prognosis (reviewed by Cohn and Tweddle, 2004). MYCN
is a proto-oncogene directly involved in neuroblastoma tumorige-
nesis, evident by the spontaneous development of neuroblastoma
in a MYCN dose-dependent manner in transgenic murine models
(Weiss et al., 1997).
Direct inhibition of MYCN has not yet been clinically success-
ful (Gustafson and Weiss, 2010), consequently there is a focus on
developing therapeutic strategies directed at destabilizing MYCN
protein, and at the downstream targets or pathways which mediate
the oncogenic functions of MYCN, and drive the aggressive behav-
ior and progression of MYCN amplified tumors. This review will
focus on three selected MYCN target genes p53, SKP2, and DKK3,
which we have previously identified as being directly or indirectly
regulated by MYCN (Bell et al., 2007a; Chen et al., 2010), and
strategies that are now being or could be employed in the future
to target them, particularly in MYCN amplified neuroblastoma.
MYCN
MYCN belongs to the MYC family of basic-helix-loop-helix-
leucine zipper (bHLH-LZ) transcription factors which also
includes c-MYC, and MYCL. Deregulated expression of Myc fam-
ily members have been implicated in the genesis of several human
cancers. Consistent with this, studies have shown that MYC con-
tributes to numerous aspects of tumorigenesis including unre-
stricted cellular growth and proliferation, angiogenesis, inhibition
of differentiation, metastasis, genomic instability, and reduced cell
adhesion (reviewed by Adhikary and Eilers, 2005).
The MYCN gene located at 2p24 encodes a 64 kDa nuclear
phosphoprotein, which contains a transcriptional activation
domain at the N-terminal, and a transcriptional regulation
domain with a bHLH-LZ motif at the C-terminal (Schwab, 2000).
In contrast to c-MYC, which is expressed in a wide variety of
embryonic and adult tissues, MYCN expression is limited to the
developing nervous system and selected other sites (Cohn and
Ikegaki, 2000).
TRANSACTIVATION AND REPRESSION OF TARGET GENES BY MYCN
MYC proteins function as active heterodimers with MAX via their
conserved bHLH-LZ domains to exert transcriptional activation
via direct binding to E-Box motifs (CANNTG) within target gene
promoters and the subsequent recruitment of multiple transcrip-
tional coactivators. Heterodimerization with MAX is required for
direct binding of MYC proteins to DNA. Myc family members
have short half-lives and their expression levels are highly regu-
lated. In contrast, MAX is stable and constitutively expressed, and
normally present in stoichiometric excess to MYC, which suggests
that the abundance of active heterodimers is dependent on the
levels of MYC proteins (reviewed by Grandori et al., 2000).
In contrast to transactivation mediated by MYC,transcriptional
repression is independent of E-Box binding and has been shown to
involve recruitment of MYC proteins to target gene promoters by
Miz-1 and disruption of the interaction between transcriptional
complexes. MYC mediated transcriptional repression via Miz-1
has been shown for p15INK4B (Staller et al., 2001) and p21CIP1
(Seoane et al., 2002). Other candidate proteins which have been
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proposed to recruit MYC to core promoters include TFII-I, NF-
Y, YY-1, and SP1 (reviewed by Wanzel et al., 2003; Adhikary and
Eilers, 2005).
IDENTIFYING MYCN TARGET GENES
The identification of MYCN target genes enables a greater under-
standing of MYCN driven neuroblastoma tumorigenesis and
promotes the identification of potential targets for therapeutic
intervention in the treatment of neuroblastoma. A vast number
of c-MYC target genes have been identified and can be found
at http://myccancergene.org/site/mycTargetDB.asp (Zeller et al.,
2003), however less is known about the target genes of MYCN.
It has been estimated that MYC is bound to ∼25,000 sites within
the human genome (reviewed by Adhikary and Eilers, 2005). Early
studies found that several c-MYC target genes were expressed in
some neuroblastoma cell lines with MYCN amplification, but not
all, suggesting that other cell specific factors may be important
(Ben-Yosef et al., 1998). More recent studies have reported sig-
nificant overlap between c-MYC and MYCN-regulated gene sets
(Laurenti et al., 2008; Westermann et al., 2008).
Target genes downstream of MYCN can be classified as direct
or indirect. Direct target genes of MYCN can be defined as genes
which possess a MYCN binding E-Box motif located within close
proximity to the transcriptional start site of the gene and/or for
which MYCN has been shown to directly bind to the gene pro-
moter to drive transcription. This involves using methods such as
electrophoretic mobility shift assay (EMSA), reporter gene assays,
and/or more recently Chromatin Immunoprecipitation (ChIP)
analysis, a technique which allows specific protein-DNA interac-
tions to be isolated. Indirect target genes of MYCN are genes which
are altered as a consequence of other genes or pathways that are
directly regulated by MYCN (Bell et al., 2010).
There are several approaches used to identify target genes of
transcription factors such as MYCN. The candidate gene approach
involves selecting genes which are involved in the known biolog-
ical functions of MYCN, such as cell proliferation. Furthermore
due to the homology between the Myc family members, the candi-
date gene approach is often used to determine whether previously
known c-MYC target genes are also MYCN target genes (Bell et al.,
2010). Alternatively, the inference approach is used and is based on
identifying putative target genes by the presence of MYCN/MAX
binding sites within their gene regulatory regions (Dang, 1999).
Moreover, target genes may also be identified based on their dif-
ferential expression in conditions with varying MYCN expression
levels, such as MYCN regulatable expression systems or comparing
MYCN amplified versus non-amplified cell lines and/or tumors.
The latter is often performed using microarray based genome-wide
approaches (reviewed by Bell et al., 2010).
More recently, with the development of ChIP and advances
in technology, genome-wide in vivo approaches for identifying
protein-DNA interactions have become available, including ChIP-
cloning, ChIP-chip, and the latest and increasingly popular, ChIP-
seq. These techniques enable the identification of direct target
genes, and the specific in vivo binding sites within the genome
without prior knowledge. Direct targets may be further confirmed
using quantitative PCR based ChIP analysis (Wu et al., 2006).
Interestingly, a ChIP-chip array study of MYCN/c-MYC target
genes in neuroblastoma demonstrated that distinct MYCN/c-MYC
target gene expression was associated with overall survival, and
independent of well-established markers such as MYCN ampli-
fication, disease stage, and age at diagnosis (Westermann et al.,
2008).
p53
p53 was discovered over three decades ago as one of the first
tumor suppressors (Lane and Crawford, 1979; Linzer and Levine,
1979) and has since been shown to be the most frequently mutated
gene in human cancer. p53 is involved in the regulation of several
processes that contribute to its central role in maintaining genomic
stability and tumor suppression, including cell cycle arrest, apop-
tosis, senescence, differentiation, autophagy, DNA repair, angio-
genesis, cell migration, metabolism, and the immune response.
The TP53 gene located at chromosome position 17p13.1 encodes
a 53 kDa nuclear phosphoprotein that consists of an N-terminal
transactivation domain (TAD), a central sequence-specific DNA
binding domain (DBD), a tetramerization domain, and a highly
basic C-terminal regulatory domain. Nuclear export signals (NES)
are located within both the N- and C-termini, and three lysine-
rich nuclear localization signals (NLS) are located within the
C-terminal (reviewed by Bai and Zhu, 2006). Identified more
recently, p63 and p73 are two homologs which share structural
and functional similarity to p53 and belong to the p53 family
(reviewed by Levrero et al., 2000).
THE p53/MDM2/p14ARF PATHWAY
Under normal cellular conditions, p53 is maintained at low levels
mainly due to MDM2, an E3 ubiquitin ligase and the critical neg-
ative regulator of p53 (Honda et al., 1997). This is supported by
the observed embryonic lethality of MDM2 knockout mice and
their rescue by the concomitant deletion of p53 (Jones et al., 1995;
Montes de Oca Luna et al., 1995). MDM2 is a direct transcriptional
target of p53 and is induced in response to p53 activation thereby
forming a tightly regulated negative feedback loop. MDM2 directly
binds to the N-terminal TAD of p53 to inhibit p53 transcriptional
activity (Momand et al., 1992), as well as promoting nuclear export
and targeting p53 for ubiquitin mediated proteasome degradation
(Honda et al., 1997; Tao and Levine, 1999a). p14ARF is a tumor sup-
pressor and the negative regulator of MDM2. Studies have shown
that p14ARF promotes p53 stability and activity by inhibiting
MDM2-mediated degradation of p53 via direct interaction with
MDM2 and inhibiting its E3 ligase activity (Honda and Yasuda,
1999), preventing MDM2 and p53 nuclear export (Tao and Levine,
1999b), sequestering MDM2 within the nucleolus (Weber et al.,
1999), and also by promoting MDM2 degradation (Zhang et al.,
1998). Activated p53 can subsequently downregulate the expres-
sion of p14ARF (Robertson and Jones, 1998; Stott et al., 1998).
MDMX is a homolog of MDM2 and a negative regulator of p53.
It has been shown to enhance MDM2-mediated ubiquitination
and degradation of p53, and repress p53-mediated transcription
(reviewed by Marine et al., 2007; Kruse and Gu, 2009). Inter-
estingly, MDM2 can promote ubiquitination and degradation of
MDMX, an effect which is stimulated by p14ARF and which cor-
relates with the ability of p14ARF to bind MDM2 (Pan and Chen,
2003; Figure 1).
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FIGURE 1 | MYC proteins and the p53/MDM2/p14ARF pathway. In
response to cellular stresses p53 can mediate the expression of genes
involved in various cellular responses such as apoptosis (e.g., BAX, NOXA,
and PUMA), cell cycle arrest (e.g., p21CIP1), differentiation, DNA repair or
senescence. p53, MDM2 and p14ARF form an autoregulatory feedback loop to
tightly regulate p53 expression and activity. p14ARF can be activated in
response to aberrant oncogenic factors such as c-MYC, and possibly MYCN
(as indicated by the dashed line). p14ARF can also exhibit p53-independent
tumor suppressor activity by directly binding and inhibiting the activity of
c-MYC and MYCN. Both p53 and MDM2 are direct target genes of MYCN.
MDM2 can regulate MYCN mRNA stability and translation, thereby forming a
positive feedback loop.
ACTIVATION AND FUNCTION OF p53
In response to a variety of intrinsic and extrinsic cellular stresses
such as DNA damage, oncogenic activation, deprivation of growth
factors/signals, ribonucleotide depletion, microtubule disruption,
and hypoxia, there is stabilization, nuclear accumulation, and
activation of p53. This is predominantly regulated by post-
translational modifications conferred on the p53 protein, such
as phosphorylation, ubiquitylation, acetylation, and sumoylation
(Bode and Dong, 2004). N-terminal modifications of p53 act to
inhibit the p53-MDM2 interaction thereby preventing MDM2-
mediated inactivation and degradation of p53. In addition, modi-
fications within the DBD and C-terminal of p53 have been shown
to increase p53 sequence-specific DNA binding and relieve the
inhibitory effect of the C-terminal regulatory domain on the core
DBD of p53, respectively (reviewed by Appella and Anderson,
2001). Once activated, p53 initiates cellular responses via tran-
scriptional regulation of a vast repertoire of downstream target
genes encoding proteins and microRNAs (miRNAs), as well as
transcriptional independent functions. The type of response can
be dependent on several factors that are both extrinsic and intrin-
sic to the cell, such as cell type, cellular environment, oncogenic
lesions present in the cell, and also stress type (Jimenez et al., 1999;
Vousden and Lu, 2002).
p53 functions as an active tetramer to directly bind to a con-
sensus p53 DNA binding sequence consisting of two adjacent
10 bp half-sites 5′-RRRCWWGYYY-3′ (R=A or G, Y =C or T,
W =A or T), separated by 0–13 bp, located within the promot-
ers of downstream target genes (el-Deiry et al., 1992). In contrast,
most genes which are repressed by p53 tend to lack p53 DNA
binding sites within their promoters (Mirza et al., 2003). To date
several mechanisms for p53-mediated transcriptional repression
have been identified (reviewed by Wang et al., 2010a; Bohlig and
Rother, 2011). The total number of p53 target genes is unknown
however it has been shown that 4852 genes within the human
genome contain at least one consensus p53 DNA binding site. Fur-
thermore, the identification of non-consensus p53 binding sites
also contributes to the ever expanding repertoire of p53 target
genes (reviewed by Menendez et al., 2009). p53 target genes have
been previously reviewed (Mirza et al., 2003; Harms et al., 2004;
Nakamura, 2004; Riley et al., 2008; Wang et al., 2010a).
In recent years, p53 has also been shown to regulate the tran-
scriptional expression and maturation of miRNAs, a class of
endogenously expressed small (∼18–25 nt) non-coding RNA mol-
ecules involved in post-transcriptional regulation of gene expres-
sion (Lujambio and Lowe, 2012). p53 has been found to upregulate
the expression of the miR-34 cluster which is reported to mediate
several tumor suppressive functions of p53 including senescence,
cell cycle arrest, and apoptosis (Bommer et al., 2007; Chang et al.,
2007; He et al., 2007; Raver-Shapira et al., 2007; Tarasov et al.,
2007). Consistent with this, reduced levels of miR-34 have been
observed in both tumors and cell lines, including neuroblastoma
(Bommer et al., 2007; Chang et al., 2007; Tarasov et al., 2007;
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Welch et al., 2007; Feinberg-Gorenshtein et al., 2009). Additionally,
p53 has also been reported to induce the expression of miR-192,
miR-215, miR-145, and miR-107, of which miR-145 was shown to
inhibit c-MYC expression (Braun et al., 2008; Georges et al., 2008;
Sachdeva et al., 2009; Yamakuchi et al., 2010). Conversely, several
miRNAs have been found to regulate the abundance and activity
of p53, such as miR-380-5p, which is associated with poor outcome
in MYCN amplified neuroblastoma (Swarbrick et al., 2010).
p53 is also able to exert functions via protein-protein inter-
actions, and several proteins involved in cell cycle control, DNA
repair, gene transcription, and apoptosis have been shown to bind
to p53 (Moll et al., 2005; Braithwaite et al., 2006; Speidel et al.,
2006). Although p53 is a nuclear protein, a fraction of p53 has been
found within the cytoplasm, exhibiting non-nuclear transcrip-
tional independent activities. Cytoplasmic p53 has been reported
to directly interact with members of the BCL2 family including
anti-apoptotic BCLxL and BCL2, and proapoptotic BAX and BAK
which result in mitochondria membrane permeability, release of
cytochrome C, and apoptosis (reviewed by Moll et al., 2005).
p53 PATHWAY INACTIVATION AND CANCER
The crucial role p53 plays in tumor suppression is emphasized
by observations that the p53 pathway is abrogated in around half
of all cancers due to an inactivating p53 mutation, and the rest
have impaired upstream or downstream p53 pathways (Brown
et al., 2009). This is further supported by the severe predisposition
to cancers observed in individuals with Li-Fraumeni syndrome
(Evans and Lozano, 1997). Additionally, p53 null mice are reported
to develop a range of spontaneous tumors, most commonly T-cell
lymphomas (Donehower, 1996).
The frequency of p53 mutations varies from 10 to 70% across
different cancers types, and are more common in solid tumors
compared with hematological malignancies (Calin et al., 1999;
Soussi et al., 2000). The majority are missense mutations result-
ing in single amino acid substitutions and map within the DBD
of p53 (Brosh and Rotter, 2009). In tumors and cell lines, muta-
tional inactivation predominantly leads to the accumulation of
high levels of mutant p53 protein. Some p53 mutants have been
shown to exert a dominant negative effect on wild-type (wt) p53
owing to the requirement for p53 to function as an active tetramer
(Vousden and Lu, 2002). p53 mutations identified to date can be
found within publically available p53 databases such as The Inter-
national Agency for Research on Cancer (IARC) TP53 Mutation
Database1 and The p53 Website2. In addition to loss of tumor sup-
pressive function and exerting dominant negative effects against
wt p53, it has become increasingly evident that p53 mutants can
exhibit new functions independent of wt p53 and can vary depend-
ing on the mutation. These new gain-of-function mutants have
been reported to play a role in promoting tumorigenesis includ-
ing increased metastasis and genomic instability, and resistance
to anti-cancer therapies (reviewed by Xu, 2008; Brosh and Rotter,
2009; Oren and Rotter, 2010; Hanel and Moll, 2012). Studies using
murine models have observed that mutant p53 knock-in mice
develop more aggressive and metastatic tumors in comparison to
1http://www-p53.iarc.fr/
2http://p53.free.fr/
p53 null mice, and that the different p53 mutants are associated
with distinct tumor patterns (Lang et al., 2004; Olive et al., 2004;
Lozano, 2007; Song et al., 2007; Oren and Rotter, 2010).
The prognostic and predictive significance of p53 somatic
mutations in human cancer have been extensively evaluated over
the past 15 years however due to inconsistencies have failed to
reach clinical practice to guide treatment. This has predominantly
been attributed to the use of immunohistochemistry to detect p53
accumulation as a marker of p53 mutational inactivation which
is inaccurate as this detects both wt and mutant p53 in most
cases. More recent studies which have used gene sequencing to
determine p53 status have obtained more consistent results. There
is a general trend associating p53 mutations with a poor prog-
nosis and resistance to chemo- and radiotherapy. This has been
shown for malignancies of the breast, head and neck, colorectum,
and hematopoietic system (Brosh and Rotter, 2009; Olivier and
Taniere, 2011).
In addition to p53 mutations, amplification, and/or overexpres-
sion of MDM2 or MDMX, as well as p14ARF mutation, deletion,
or methylation can also lead to abrogation of the p53 pathway
(reviewed by Brown et al., 2009). Similar to p53 null mice, mice
deficient in p14ARF, or overexpressing MDM2 or MDMX also
developed spontaneous tumors, albeit at a slower rate (Jones et al.,
1998; Kamijo et al., 1999; Xiong et al., 2010). Abrogation of p53
function may also occur as the result of viral inactivation such as
the human papillomavirus, or impaired upstream signaling and/or
downstream mediators of p53 function, such as inactivation of
ATM or CHK2, or genes involved in the apoptotic response, and/or
cell cycle arrest. Although it is not clear why certain mechanisms
of p53 pathway inactivation are favored in some tumors but not
others, it is likely to be influenced by the various selective pressures
acting upon the cancer (Junttila and Evan, 2009).
Interestingly in contrast to p53, p63, and p73 are rarely mutated
in human cancers and neither p63 nor p73 knockout mice exhibit
an increased susceptibility to developing spontaneous tumors
(Moll and Slade, 2004).
p53 AND NEUROBLASTOMA
p53 accumulation and function in neuroblastoma
In contrast to many other human cancers, p53 mutations in neu-
roblastoma are rare, occurring in ∼3% of cases analyzed to date
(Imamura et al., 1993; Komuro et al., 1993; Ohgaki et al., 1993;
Vogan et al., 1993; Castresana et al., 1994; Hosoi et al., 1994; Kusa-
fuka et al., 1997; Manhani et al., 1997; Omura-Minamisawa et al.,
2001; Tweddle et al., 2001b; Carr-Wilkinson et al., 2010). Despite
this, p53 has been reported to accumulate in neuroblastoma, which
has been suggested to be due to the embryonic nature of these
tumors, reflecting a failure of precursor cells to mature (Sidell
and Koeffler, 1988; Davidoff et al., 1992). This is consistent with
studies which have shown a decrease in p53 expression follow-
ing retinoic acid induced in vitro differentiation of neuroblastoma
cell lines (Sidell and Koeffler, 1988; Davidoff et al., 1992; Chen
et al., 2007),and also during neuronal development/differentiation
(Eizenberg et al., 1996; Ferreira and Kosik, 1996). In addition
siRNA mediated inhibition of p53 in neuroblastoma cell lines
led to morphological evidence of differentiation (Carr-Wilkinson
et al., 2011). The presence of high levels of accumulated wt p53
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suggests that neuroblastoma circumvent the tumor suppressive
properties of p53 by a mechanism independent of mutation. Early
studies reported cytoplasmic sequestration of wt p53 as a non-
mutational mechanism for p53 inactivation and accumulation in
neuroblastoma (Moll et al., 1995, 1996). To date several mecha-
nisms for cytoplasmic sequestration of p53 in neuroblastoma have
been proposed, including masking of the p53 C-terminal nuclear
localization signal (Ostermeyer et al., 1996), hyperactive nuclear
export (Stommel et al., 1999), binding to the cytoplasmic anchor,
Parc (Nikolaev and Gu, 2003; Nikolaev et al., 2003), aberrant
hyperubiquitylation of p53 (Becker et al., 2007), and MDMX and
MDM2-mediated cytoplasmic tethering (Ohtsubo et al., 2009). In
contrast, a number of studies including our own have reported
predominantly nuclear localization and/or functional p53 in neu-
roblastoma (Layfield et al., 1995; Hoehner et al., 1997; Danks et al.,
1998; Isaacs et al., 1998; McKenzie et al., 1999; Smart et al., 1999;
Keshelava et al., 2000, 2001; Tweddle et al., 2001a,b; Cui et al., 2002;
Goldschneider et al., 2004; Chen et al., 2007, 2010; Xue et al., 2007;
Kurata et al., 2008; Van Maerken et al., 2011; Gamble et al., 2012).
The conflicting results over the localization and function of p53
are likely to be due to the different p53 antibodies and the crite-
ria used to define functional p53. Interestingly, despite functional,
transcriptionally active p53, we have previously reported a failure
for MYCN amplified neuroblastoma cells to G1 arrest after DNA
damage (Tweddle et al., 2001b; Bell et al., 2006) and have recently
shown that the outcome of the p53-mediated response to DNA
damage in neuroblastoma cell lines is determined by both mor-
phological subtype (neuronal or substrate adherent) and MYCN
expression (Carr-Wilkinson et al., 2011).
Inactivation of the p53 pathway and resistance to cytotoxic therapy
Most neuroblastomas initially respond well to cytotoxic agents
however the disease frequently relapses with acquired resistance to
therapy thus posing a major problem in the treatment of patients
with high-risk neuroblastoma. Consequently, gaining a greater
understanding into the mechanisms behind resistance to cytotoxic
therapies could lead to the development and use of novel thera-
pies in progressing or relapsed disease (Tweddle et al., 2001a). An
important mechanism for chemo- and radioresistance is inactiva-
tion of the p53 pathway (reviewed by Levine, 1997). The initial
good response to chemotherapy may be partly due to the presence
of functional p53 at diagnosis, and the development of resistance
at relapse may be the result of acquired p53 inactivation at a later
stage (reviewed by Tweddle et al., 2003). Consistent with this, of the
few p53 mutations which have been identified in neuroblastoma to
date, the majority were in tumors from patients with progressive
or relapsed disease and/or post-chemotherapy (Imamura et al.,
1993; Komuro et al., 1993; Ohgaki et al., 1993; Vogan et al., 1993;
Castresana et al., 1994; Hosoi et al., 1994; Kusafuka et al., 1997;
Manhani et al., 1997; Omura-Minamisawa et al., 2001; Tweddle
et al., 2001b; Carr-Wilkinson et al., 2010). Similarly, despite the
frequency being slightly higher than those in tumors, p53 muta-
tions in neuroblastoma cell lines are also rare, and the majority
were also identified in cell lines established at relapse (Tweddle
et al., 2003; Carr et al., 2006; Table 1).
Using a pair of neuroblastoma cell lines derived from the
same patient, before and after cytotoxic therapy, we previously
demonstrated that the cell line derived after therapy, at disease
relapse, had mutant non-functional p53, and was more resistant
to chemotherapy compared to the cell line derived at diagno-
sis before therapy, which had wt functional p53 (Tweddle et al.,
2001a). Other studies have also correlated loss of p53 function
with drug resistance in neuroblastoma cell lines, and found that
transfection of wt p53 drug sensitive cell lines with E6 vectors
led to chemoresistance (Keshelava et al., 2000, 2001). In line with
these observations, we recently reported that the presence of a
p53 mutation was independently prognostic for overall survival in
neuroblastoma patients (Carr-Wilkinson et al., 2010).
In addition to p53 mutations,MDM2 amplification,and p14ARF
deletion or methylation have also been reported in neuroblas-
toma tumors and cell lines, most of which were from patients with
progressive or relapsed disease and/or post-chemotherapy (Corvi
et al., 1995; Omura-Minamisawa et al., 2001; Thompson et al.,
2001; Gonzalez-Gomez et al., 2003; Su et al., 2004; Carr et al.,
2006; Spitz et al., 2006; Caren et al., 2008; Carr-Wilkinson et al.,
2010; Wolf et al., 2010). Interestingly, in our recent study of paired
neuroblastoma tumors established at diagnosis and relapse which
demonstrated a high frequency of p53/MDM2/p14ARF pathway
abnormalities in relapsed neuroblastoma, a higher frequency of
abnormalities involving MDM2 amplification, and p14ARF inac-
tivation (35%) compared to p53 mutations (15%) was observed.
In all three cases with MDM2 amplification and 8/12 cases with a
p14ARF alteration, the abnormality was present in both the diag-
nostic and relapsed specimen, whereas in 5/6 cases where a p53
mutation was detected it was present in the relapsed specimen
alone. This therefore suggests that for MDM2 amplification and
p14ARF alterations their presence predisposes to relapse whereas
p53 mutations are acquired at relapse (Carr-Wilkinson et al.,
2010).
In recent years there has been increased interest in assessing
whether polymorphisms can influence cancer risk and clinical
outcome. A single-nucleotide polymorphism (SNP) in the MDM2
promoter (SNP309T to G) leading to high levels of MDM2 expres-
sion has been found in some tumors and is associated with a poor
prognostic outcome, including neuroblastoma (Cattelani et al.,
2008; Perfumo et al., 2008). In p53, a SNP at codon 72 which
leads to an Arg>Pro substitution has previously been identified,
and the Arg72 variant has been shown to exhibit enhanced apop-
totic capability compared with the Pro72 variant (Dumont et al.,
2003). Very recently, analysis of the p53 codon 72 Arg/Pro poly-
morphism identified the Pro/Pro phenotype as an independent
marker of poor prognosis in neuroblastoma patients, and in vitro
led to reduced levels of apoptosis in response to chemotherapy
and irradiation (Cattelani et al., 2012).
MYCN mediated upregulation of p53 as a mechanism for MYCN
induced apoptosis in neuroblastoma
Members of the Myc family are known to play a paradoxical role in
driving both cellular proliferation and inducing apoptosis, which
is thought to provide a safeguard mechanism to prevent uncon-
trolled cellular proliferation and oncogenic transformation. This
paradox is observed histologically by a high mitosis-karyorrhexis
index, a combined index of both proliferation and apoptosis, in
both human MYCN amplified neuroblastoma tumors (Shimada
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et al., 1995, 1999; Goto et al., 2001; Altungoz et al., 2007) and TH-
MYCN transgenic mouse neuroblastoma tumors (Moore et al.,
2008).
p53 has long been known to be a direct target gene of c-MYC,
and mediate c-MYC induced apoptosis (Reisman et al., 1993; Her-
meking and Eick, 1994; Roy et al., 1994; Zeller et al., 2003). Initial
studies in neuroblastoma showed that MYCN amplified tumors
expressed significantly higher levels of p53 mRNA in comparison
with non-amplified tumors (Raschella et al., 1991; Berwanger et al.,
2002; Westermann et al., 2008), and higher p53 protein expression
in the presence of ectopic MYCN in cell lines (Cui et al., 2005; Bell
et al., 2006; Sugihara et al., 2006). Using ChIP-chip arrays MYCN
was reported to bind to an E-Box within the p53 promoter, how-
ever this study did not include the functional upregulation of p53
(Westermann et al., 2008). Most recently, in a study of p53 expres-
sion, accumulation, and function in neuroblastoma in relation to
MYCN amplification and expression, we demonstrated that p53
protein expression correlated with MYCN protein expression in
both neuroblastoma tumors and cell lines (Chen et al., 2010). Fur-
thermore, we demonstrated that p53 was functional and exhibited
greater transcriptional activity in the presence of MYCN leading
to the increased expression of several p53 target genes. Finally, we
showed that MYCN mediates transactivation of p53 by interact-
ing directly with the same E-Box motif (CATGTG) as previously
reported for c-MYC (Reisman et al., 1993; Figure 1), and is likely
to be an important and direct mechanism by which MYCN is able
to sensitize cells to p53-mediated apoptosis (Chen et al., 2010).
This is consistent with, and may help to explain why human
MYCN amplified and TH-MYCN transgenic mouse neuroblas-
toma tumors have high levels of apoptosis, and MYCN amplified
and Tet21N MYCN+ neuroblastoma cells undergo higher levels
of apoptosis in response to chemotherapeutic agents (Fulda et al.,
1999, 2000; Paffhausen et al., 2007; Chesler et al., 2008), irradia-
tion (Bell et al., 2006), and MDM2-p53 antagonists (Gamble et al.,
2012). Certainly, siRNA mediated inhibition of p53 led to reduced
levels of apoptosis in MYCN amplified neuroblastoma cell lines
(Chesler et al., 2008; Chen et al., 2010).
Further support for MYCN driven p53-dependent apoptosis
being an important mechanism for tumor suppression in neu-
roblastoma comes from in vivo work using p53 or Mdm2 hap-
loinsufficient models of neuroblastoma. MYCN driven tumor
formation had higher penetrance and reduced latency in p53
haploinsufficient mice, and chemotherapy induced apoptosis was
shown to be p53-dependent, in which apoptosis was signifi-
cantly reduced in TH-MYCN p53+/− tumors compared with
TH-MYCN p53+ /+ tumors (Chesler et al., 2008). In con-
trast, Mdm2 deficiency suppressed MYCN driven neuroblas-
toma tumorigenesis, as evident by an extended tumor latency
and survival and reduced tumor incidence and growth in TH-
MYCN Mdm2+/− transgenic mice compared with TH-MYCN
Mdm2+ /+mice. Additionally, TH-MYCN Mdm2+/− tumors
commonly exhibited methylation of p19ARF . These observa-
tions thereby demonstrate the necessity of MYCN to over-
come p53-mediated tumor suppression during neuroblastoma
tumorigenesis either via direct inhibition of p53 by MDM2
or suppression of the p14ARF/p53 pathway (Chen et al.,
2009).
The ability of MYCN to induce apoptosis, such as through
direct upregulation of p53, may be a potential pathway for spon-
taneous regression. Certainly, a study analyzing MYCN/c-MYC
target gene expression and outcome in neuroblastoma has previ-
ously suggested p53 as a strong candidate involved in spontaneous
regression of 4s tumors (Westermann et al., 2008).
MYCN and p53 are both expressed in the normal embry-
onic developing nervous system, during the phase of precursor
cell expansion prior to the onset of differentiation. In the con-
text of normal embryonic development, direct upregulation of
p53 by MYCN may be an important mechanism to eliminate
any rapidly proliferating neuroblasts exposed to potential terato-
gens, to prevent deregulated proliferation and aberrations during
development.
In addition to direct transcriptional upregulation of p53, c-
MYC has been previously reported to sensitize cells to increased
apoptosis via induction of p14ARF mediated upregulation of p53
expression, stability, and activity (Zindy et al., 1998). Due to the
homology between c-MYC and MYCN, MYCN may also be able
to stabilize p53 via p14ARF, however this remains to be proven
experimentally (Figures 1 and 2).
Mechanisms of p53 inactivation and evasion of p53-dependent
apoptosis in MYCN amplified neuroblastoma
Several lines of evidence from published literature lend support
to the notion that during the process of neuroblastoma pro-
gression there is evasion of p53-mediated tumor suppression
via inactivation of the p53/MDM2/p14ARF pathway (reviewed by
Van Maerken et al., 2009b) as well as a requirement for MYCN
amplified neuroblastoma to circumvent MYCN driven apoptosis
(reviewed by Hogarty, 2003). In vivo studies have demonstrated
the importance of the p53 pathway in neuroblastoma (Chesler
et al., 2008; Chen et al., 2009). Potential mechanisms whereby
MYCN amplified tumors can overcome p53-mediated tumor
suppression in neuroblastoma are discussed below.
MYCN amplification and inactivation of the p53/MDM2/p14ARF
pathway in neuroblastoma
There is evidence from neuroblastoma cell line studies that MYCN
amplified neuroblastoma cells may circumvent MYCN driven p53-
dependent apoptosis by selecting for cells with aberrations in the
p53/MDM2/p14ARF pathway. Analysis of neuroblastoma cell lines
reported to date with aberrations in the p53/MDM2/p14ARF path-
way demonstrates that 31/40 (78%) of these cell lines are MYCN
amplified and predominantly established following previous cyto-
toxic therapy at relapse (Table 1), when abnormalities of the
p53 pathway in neuroblastoma tumors have also been previously
reported (reviewed by Tweddle et al., 2003; Carr-Wilkinson et al.,
2010). In contrast, the proportion of neuroblastoma tumors with
aberrations in the p53/MDM2/p14ARF pathway which are MYCN
amplified are lower than in cell lines (Corvi et al., 1995; Gonzalez-
Gomez et al., 2003; Su et al., 2004; Spitz et al., 2006; Caren et al.,
2008; Carr-Wilkinson et al., 2010), therefore it is possible that these
abnormalities are selected for during the in vitro establishment
and/or maintenance of these cell lines. It is however important to
note that MYCN amplification and/or overexpression is unlikely to
be the only selection pressure for p53 inactivation as aberrations in
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Table 1 | MYCN status and aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines.
Cell Line MYCN
Status
p53
Mut
p53 Mut
Codon
MDM2
Amp
p14ARF
Deln
p14ARF
Meth
Diagnosis/
Relapse§
Reference
ACN nMNA Yes 113 Relapse Forbes et al. (2008)
CHLA-119 MNA1 Yes 342 Relapse Keshelava et al. (2001)
CHLA-172 nMNA1 Yes 216 Relapse Keshelava et al. (2001)
CHLA-90 nMNA Yes 286 Relapse Keshelava et al. (2001)
CLB-Pe MNA Yes 176 Relapse Mergui et al. (2008)
IGRN91 MNA Yes a Relapse Goldschneider et al. (2004, 2006)
IGR-NB8 MNA Yes 326 Diagnosis Goldschneider et al. (2006)
KELLY/N-206 MNA Yes 177 Unknown Mergui et al. (2008), Van Maerken et al. (2011)
KP-N-YS MNA Yes 135 Diagnosis2 Forbes et al. (2008)
LAN-1 MNA Yes 182 Relapse Davidoff et al. (1992), Van Maerken et al. (2011)
LAN-2 MNA Yes 337 Diagnosis Van Maerken et al. (2011)
NB4 MNA Yes 173 Diagnosis3 Teitz et al. (2002)
NB6 MNA Yes 282 Relapse Teitz et al. (2002)
NB8 MNA Yes b Diagnosis Teitz et al. (2002), Van Maerken et al. (2011)
NB12 MNA Yes 173 Unknown Teitz et al. (2002)
NB13 MNA Yes 173 Unknown Teitz et al. (2002)
NB14 MNA Yes c Diagnosis Teitz et al. (2002)
NB15 MNA Yes 248 Unknown Teitz et al. (2002)
NB20 MNA Yes 248 Unknown Teitz et al. (2002)
NLF MNA Yes 203 Diagnosis4 Van Maerken et al. (2011)
NMB MNA Yes 245 Relapse Goldman et al. (1996)
SJNB-4 MNA Yes 176 Relapse McPake et al. (1998)
SKNAS nMNA Yes d Relapse Goldschneider et al. (2006), Nakamura et al.
(2007), Van Maerken et al. (2011)
SKNBE2C MNA Yes 135 Relapse Kaghad et al. (1997), Keshelava et al. (2001),
Tweddle et al. (2001a,b) Van Maerken et al. (2011)
SK-N-DZ MNA Yes 110 Relapse5 Forbes et al. (2008)
SK-N-FI nMNA Yes 246 Relapse Van Maerken et al. (2006, 2011)
TGW MNA Yes 282 Relapse Sugiyama et al. (2003)
NGP MNA Yes Relapse Corvi et al. (1995), Tweddle et al. (2001b), Van
Maerken et al. (2011)
NB1691 MNA Yes Relapse McKenzie et al. (1999)
CHLA134 MNA Yes Relapse Keshelava et al. (2001)
LS MNA Yes Relapse Corvi et al. (1995), Carr et al. (2006)
TR-14 MNA Yes Relapse Carr et al. (2006), Van Maerken et al. (2011)
LAN-6 nMNA Yes Relapse Keshelava et al. (2001), Thompson et al. (2001),
Van Maerken et al. (2011)
SHEP nMNA Yes Relapse Tweddle et al. (2001b), Carr et al. (2006), Van
Maerken et al. (2011)
CHLA-101 MNA Yes e Relapse Thompson et al. (2001)
CHLA-174 nMNA Yes Relapse Thompson et al. (2001)
CHLA-179 MNA Yes Relapse Thompson et al. (2001)
STA-NB-3 MNA Yes Relapse6 Van Maerken et al. (2011)
GIMEN nMNA Yes Relapse Carr et al. (2006)
PER-108 MNA Yes Relapse Carr et al. (2006)
Mut, mutation; Amp, amplification; Deln, deletion; Meth, methylation; MNA, MYCN amplified; nMNA, non-MYCN amplified.
§Any cell line established prior to chemo/radiotherapy was classified as established at diagnosis and any cell lines established post-treatment was classified as
established at relapse.
1Personal communication with P. Reynolds, 2Personal communication with T. Sugimoto, 3Personal communication with S. Ragsdale, 4Personal communication with
G. Brodeur, 5Personal communication with L. Helson, 6Personal communication with P. Ambros.
aDuplication of exons 7–9 between exons 9 and 10 resulting in an extra ∼321nts, bDeletion of codons 105-125, cDeletion of codons 126–132, dDeletion of exons 10
and 11 resulting in truncated product ∼369nts, e104 bp deletion.
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the p53 pathway are also found in non-MYCN amplified tumors
and cell lines (Table 1; Carr et al., 2006; Carr-Wilkinson et al.,
2010).
MDM2-mediated MYCN driven tumorigenesis. MDM2 is a
direct target gene of MYCN (Slack et al., 2005; Westermann et al.,
2008) and non-syntenic co-amplification of MDM2 and MYCN
has been reported in neuroblastoma (Corvi et al., 1995). Con-
sistent with observations that Mdm2 haploinsufficiency inhibits
c-MYC induced lymphomagenesis (Alt et al., 2003), MDM2 has
been shown to be necessary for MYCN to overcome p53-mediated
tumor suppression for MYCN directed centrosome amplifica-
tion and genomic instability (Slack et al., 2007), and also during
MYCN driven neuroblastoma tumorigenesis (Chen et al., 2009;
Figure 2). The importance of MDM2 in neuroblastoma patho-
genesis is further illustrated by studies which have observed that a
SNP within the MDM2 promoter (SNP309T to G) that can lead to
higher expression of MDM2 and greater inhibition of p53, is asso-
ciated with poor survival in neuroblastoma, in particular stage 4
patients with MYCN amplification (Cattelani et al., 2008; Perfumo
et al., 2008, 2009).
An additional mechanism whereby MYCN can overcome p53-
mediated apoptosis is through reduced expression of CHD5, a
tumor suppressor gene (TSG) mapping to 1p36.31, which is a
region commonly deleted in neuroblastoma and frequently cor-
related with MYCN amplification (Figure 2). CHD5 has been
shown to control proliferation, apoptosis, and senescence by
inducing p19ARF, the negative regulator of MDM2, and stabi-
lizing p53 (Bagchi et al., 2007). Low levels of CHD5 expression
have been found in neuroblastoma cell lines, as well as correlating
with MYCN amplification and poor prognosis in neuroblastoma
tumors (Thompson et al., 2003; Fujita et al., 2008; Koyama et al.,
2012).
Furthermore, MYCN can also suppress p53 through Aurora
Kinase A (AURKA), a serine/threonine kinase which plays a key
role in mitosis and is expressed at high levels in MYCN amplified
neuroblastoma (Figure 2). AURKA has been shown to directly
phosphorylate p53 at Ser-215 and Ser-315 which abrogates p53
DNA binding and transactivation of target genes (Liu et al., 2004),
and promotes MDM2-mediated destabilization and inhibition of
p53 (Katayama et al., 2004). There is additional evidence to sug-
gest that AURKA can also inhibit p53 via the AKT/MDM2 axis
in gastric cancer cells, however this remains to be shown in neu-
roblastoma (Dar et al., 2008). Interestingly, AURKA has also been
reported to stabilize MYCN, which would further promote MYCN
driven tumorigenesis (Otto et al., 2009; Figure 2).
Very recently, MDM2 was reported to play a p53-independent
role by interacting directly with MYCN mRNA and regulating
its stabilization and translation, thereby forming a positive feed-
back loop, critical for MYCN amplified neuroblastoma tumor cell
growth and survival (Gu et al., 2012; Figures 1 and 2).
Twist-1 and BMI-1 mediated inhibition of the p53 pathway.
Twist-1 which belongs to the bHLH transcription factor fam-
ily, and BMI-1, a polycomb ring finger oncogene, are both
overexpressed in several human cancers, and have been shown
to be involved in epithelial-mesenchymal transition and cancer
stemness which have clinical implications of cancer metastasis,
drug resistance, and survival (Wu et al., 2012a). Twist-1 expres-
sion has been shown to be consistently overexpressed in MYCN
amplified neuroblastoma tumors and cell lines, correlating with
MYCN expression (Valsesia-Wittmann et al., 2004). Studies have
FIGURE 2 | Summary of the potential mechanisms by which MYCN can both positively and negatively regulate p53 activity and function.
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demonstrated the ability of Twist-1 to inhibit p53 expression and
activity via both transcriptional and post-translational mecha-
nisms (Figure 2). Twist-1 has been shown to directly interact
with HOXA5, a potent transactivator of p53 (Stasinopoulos et al.,
2005). Additionally, it interferes with p53 stabilization and activ-
ity via inhibition of the p53/p14ARF pathway by reducing p14ARF
levels (Maestro et al., 1999), and inhibition of Ser-20 phosphory-
lation in response to DNA damage (Stasinopoulos et al., 2005).
Furthermore, Twist-1 has been reported to repress p53-mediated
gene transcription and stability via inhibition of p300-mediated
acetylation of p53 (Hamamori et al., 1999). Moreover, it is found
to directly interact with the DBD of p53, thereby inhibiting p53-
mediated transactivation of downstream target genes (Shiota et al.,
2008). Finally, very recently Twist-1 has also been reported to inter-
act with the C-terminal regulatory domain of p53, which hinders
post-translational modifications of p53 including Ser-392 phos-
phorylation, and promotes MDM2-mediated p53 degradation
(Piccinin et al., 2012).
BMI-1 is a direct transcriptional target of c-MYC and MYCN
and is overexpressed in∼90% of neuroblastoma, correlating with
MYCN expression (Ochiai et al., 2010; Huang et al., 2011b). It is
reported to repress the CDKN2A (p16INK4a/p14ARF) locus which
can lead to inactivation of the p53 pathway. In neuroblastoma,
BMI-1 is shown to be essential for neuroblastoma tumorigene-
sis in vitro and in vivo, cooperating with MYCN via inhibition of
MYCN driven apoptosis and downregulation of p53 expression
(Cui et al., 2007; Huang et al., 2011b). Very recently, as an addi-
tional mechanism for BMI-1 mediated p53 inactivation, BMI-1
was found to directly bind to p53 in a complex with other Poly-
comb complex proteins in neuroblastoma cells leading to increased
p53 ubiquitination and degradation (Calao et al., 2012; Figure 2).
Downregulation of NDRG1 and NDRG2 mediated p53-
dependent apoptosis. NDRG1 and NDRG2 were originally iden-
tified as a genes downregulated by MYCN (Shimono et al., 1999;
Li and Kretzner, 2003; Zhang et al., 2006, 2008). The promoter
of NDRG1 has been reported to possess a p53 binding site and
leads to p53-mediated transactivation. NDRG1 was shown to be
upregulated by p53 after DNA damage, and inhibition of NDRG1
expression by siRNA abolishes p53-dependent caspase activation
and apoptosis. Furthermore, NDRG1 has been found to suppress
metastatic cell growth (Stein et al., 2004). Similar results have
been reported for NDRG2 (Liu et al., 2008a). Downregulation
of NDRG1 and NDRG2 may therefore enable MYCN ampli-
fied and/or overexpressing neuroblastoma to evade p53 driven
apoptosis (Figure 2).
MYCN and miRNAs. The 3′-UTR of MYCN has been identified
as a direct target of miR-34a (Wei et al., 2008), a miRNA which
is directly upregulated by p53 and mediates several tumor sup-
pressive functions of p53 (reviewed by Hermeking, 2007). Studies
have shown that miR-34a plays a role in inhibiting cellular pro-
liferation and inducing apoptosis in neuroblastoma cells (Welch
et al., 2007; Cole et al., 2008). Interestingly, miR-34a is located at
1p36.23, a region showing frequent loss of heterozygosity (LOH)
in neuroblastoma and which is associated with MYCN amplifi-
cation and aggressive disease progression (reviewed by Wei et al.,
2008). Consistent with this, lower expression levels of miR-34a
have been reported to correlate with 1p36 LOH in neuroblastoma
(Welch et al., 2007; Cole et al., 2008; Feinberg-Gorenshtein et al.,
2009; Figure 2). More recently, miR-380-5p, a miRNA which is
reported to repress p53, has been shown to be expressed at high
levels in neuroblastoma correlating with poor outcome in MYCN
amplified tumors. Anti-miR-380-5p treatment restored p53 func-
tion in p53 wt neuroblastoma cell lines and inhibited the growth of
orthotopically transplanted TH-MYCN tumors (Swarbrick et al.,
2010).
THERAPEUTIC STRATEGIES TO OVERCOME MECHANISMS OF p53
INACTIVATION IN NEUROBLASTOMA
MDM2-p53 antagonists
The importance of p53 in human cancer has led to vast efforts
in the development of p53-based cancer therapeutics (reviewed
by Lane et al., 2010). One such approach is the development of
small molecule inhibitors (SMIs) which disrupt the interaction
between p53 and its negative regulator MDM2 to reactivate wt
p53, as a novel class of anti-cancer agents. This class includes
cis-imidazolines (e.g., Nutlins), spiro-oxindoles (MI compounds),
benzodiazepinediones, isoindolinones, isoquinolinones, and thio-
phenes (RITA; reviewed by (Yuan et al., 2011); (Hardcastle et al.,
2011)). All of these act by targeting the p53 binding pocket
of MDM2 to inhibit the MDM2-p53 interaction, except RITA
which binds directly to p53. Compounds that bind to the RING
domain of MDM2 and act in part by inhibiting the interaction of
MDM2 with the proteasome have also been developed and include
5-deazaflavins and tryptamines (reviewed by Yuan et al., 2011).
Nutlins were the first potent and selective inhibitors of the
MDM2-p53 interaction (Vassilev et al., 2004), in particular Nutlin-
3 has been extensively evaluated in vitro and in vivo in several types
of human cancers and the cis-imidazoline RG7112 is currently in
phase I clinical trials3 (NCT00559533 and NCT00623870). Over-
all, MDM2-p53 antagonists have been shown to activate the p53
pathway, inducing p53-dependent apoptosis and sensitizing tumor
cells to cytotoxic and other molecular targeted therapies whilst
inducing a reversible cell cycle arrest in normal cells (reviewed
by (Van Maerken et al., 2009a); (Vassilev, 2004; Shangary et al.,
2008; Korotchkina et al., 2009; Cheok et al., 2011)). In recent years,
there has been increased interest in the use of MDM2-p53 antag-
onists in a cyclotherapeutic setting to protect normal cells from
the harmful effects of chemotherapy (reviewed by Cheok et al.,
2011; van Leeuwen, 2012) and also in the identification of natural
MDM2 inhibitors (Qin et al., 2012). It is worth mentioning here
that despite structural similarities between MDM2 and MDMX,
MDM2-p53 antagonists are largely ineffective against MDMX, and
in some cases overexpression of MDMX has been reported to con-
fer resistance to MDM2 antagonists (reviewed by Wade and Wahl,
2009).
Evaluation of Nutlin-3 and other MDM2-p53 antagonists in
preclinical models of neuroblastoma have reported potent anti-
tumor effects such as induction of growth arrest, senescence,
differentiation and apoptosis, and inhibition of tumor cell pro-
liferation and metastasis (Barbieri et al., 2006; Van Maerken et al.,
3http://www.clinicaltrials.gov
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2006, 2009a, 2011; Hardcastle et al., 2011; Patterson et al., 2011;
Gamble et al., 2012). In addition, Nutlin-3 has been shown to
sensitize neuroblastoma cells to chemotherapy induced apoptosis
(Barbieri et al., 2006; Michaelis et al., 2009; Peirce and Findley,
2009a; Patterson et al., 2011). Furthermore, in line with observa-
tions that p53 is a direct target gene of MYCN and mediates MYCN
induced apoptosis,we recently reported that MYCN sensitizes neu-
roblastoma cells to both Nutlin-3 and MI63 (Gamble et al., 2012).
Moreover, there is also evidence that the MDM2 and p14ARF status
of p53 wt neuroblastoma cells can affect the response to MDM2-
p53 antagonists and warrants further investigation (Van Maerken
et al., 2011; Gamble et al., 2012).
Some studies to date have reported several p53-independent
functions of Nutlin-3, including disruption of the MDM2-p73
interaction, which leads to enhanced p73 activity, suppression of
tumor cell growth, and induction of apoptosis in p53 deficient
neuroblastoma cells (Lau et al., 2008). Additionally, Nutlin-3 has
also been shown to sensitize p53 deficient chemoresistant neurob-
lastoma cells to chemotherapy induced apoptosis via upregulation
of TAp73 and E2F1 (Ambrosini et al., 2007; Peirce and Findley,
2009b), and inhibition of P-glycoprotein (Michaelis et al., 2009).
The low incidence of p53 mutations in pediatric cancers, in par-
ticular neuroblastoma, compared with adult malignancies support
the use of MDM2-p53 antagonists as a novel therapeutic strategy
in the treatment of neuroblastoma. This is further strengthened
by reports that the MDM2 SNP309T to G is associated with poor
outcome, and that several mechanisms by which MYCN amplified
neuroblastoma can overcome p53-mediated apoptosis are depen-
dent on MDM2. Moreover, observations that inactivation of the
p53/MDM2/p14ARF pathway in relapsed neuroblastoma is pre-
dominantly due to lesions upstream of p53 combined with the
reported therapeutic efficacy of Nutlin-3 in p53 wt multi-drug-
resistant preclinical models of neuroblastoma with metastatic bur-
den (Van Maerken et al., 2009a), highly support reactivation of p53
by inhibiting MDM2 as an attractive treatment option for metasta-
tic relapsed neuroblastoma. MDM2-p53 antagonists are currently
undergoing phase I clinical evaluation in adults and are antici-
pated to enter pediatric clinical trials in the near future, including
neuroblastoma. There is however recent evidence in neuroblas-
toma cell lines suggesting that continuous exposure to Nutlin-3
can induce de novo p53 mutations, resulting in cells exhibiting
Nutlin-3 and multi-drug resistance. Consequently these results
suggest that patients treated with MDM2-p53 antagonists should
be closely monitored for the development of p53 mutations and/or
that MDM2-p53 antagonists should be given in combination with
other agents to try to prevent the development of p53 mutations
(Michaelis et al., 2011).
Aurora kinase inhibitors
The Aurora kinase family which includes Aurora A, B, and C,
have attracted much attention over recent years as potential novel
anti-cancer targets. In particular, AURKA has been shown to have
oncogenic properties and is amplified and/or overexpressed in a
range of human cancers (Maris, 2009). In neuroblastoma AURKA
has been found to be expressed at high levels in MYCN ampli-
fied tumors and required for the growth of MYCN amplified cells
(Berwanger et al., 2002; Otto et al., 2009). Studies have shown
that it suppresses p53 transcriptional activity as well as promot-
ing increased MDM2-mediated p53 degradation (Katayama et al.,
2004; Liu et al., 2004). Additionally, via direct interaction but in a
kinase independent manner,AURKA has been reported to stabilize
MYCN by preventing its ubiquitin mediated degradation (Maris,
2009; Otto et al., 2009). These observations support the therapeu-
tic potential of using AURKA inhibitors to simultaneously restore
p53 activity and destabilize MYCN in neuroblastoma. Consis-
tent with this, inhibition of AURKA expression in neuroblastoma
cells has been shown to lead to growth inhibition, increased p53
expression, and decreased MYCN expression (Otto et al., 2009).
Preclinical evaluations of a second generation AURKA inhibitor
MLN8237 in pediatric cancers including neuroblastoma have been
promising (Maris et al., 2010; Carol et al., 2011). Additionally,
Aurora kinase inhibitor CCT137690 has also shown preclinical
efficacy, downregulating MYCN, upregulating p53, and inhibiting
neuroblastoma tumor growth in vitro and in vivo. Furthermore,
consistent with the observation that AURKA is required for growth
of MYCN amplified neuroblastoma, cells expressing high levels of
MYCN were more sensitive to CCT137690 in comparison to cells
expressing low or no MYCN (Faisal et al., 2011). Several AURKA
inhibitors are currently undergoing clinical evaluations for use
as a single agent or in combination with existing chemothera-
peutics in various phase I-II trials for different human cancers
including neuroblastoma (Cheung et al., 2011). Interestingly, the
concomitant inhibition of the MDM2-p53 interaction and Aurora
kinases has been shown to act synergistically to induce apoptosis
in leukemia cells (Kojima et al., 2008), and should be assessed in
neuroblastoma.
Twist-1 and BMI-1 inhibitors
Twist-1 and BMI-1 are involved in inactivation of the p53 pathway
and are overexpressed in several cancers including neuroblas-
toma, often correlating with aggressive disease, and poor prognosis
(reviewed by Wu et al., 2012a). Strategies which can inhibit Twist-
1 and/or BMI-1 activity or expression and lead to restoration of
the p53 pathway and tumor suppression are therefore therapeu-
tically promising. In support of this, studies in neuroblastoma
have observed that MYCN functionally cooperates with Twist-1
or BMI-1 to induce neuroblastoma tumorigenesis, where overex-
pression of Twist-1 or BMI-1 is necessary for tumor growth both
in vitro and in vivo (Valsesia-Wittmann et al., 2004; Cui et al.,
2007; Huang et al., 2011b). To date no specific inhibitor of Twist-
1 has been identified, however PTC Therapeutics Inc., has very
recently announced the development of PTC596, a first in its class,
potent, oral, and selective inhibitor of BMI-1 protein expression.
The inhibitor acts by altering the post-translational modification
of BMI-1 which results in reduced levels of the protein and subse-
quently the reduced action of epigenetic complexes dependent on
BMI-14. In addition, histone deacetylase (HDAC) inhibitors and
the drug artemisinin have also been shown to reduce expression
levels of BMI-1 (Cao et al., 2011). Furthermore, as Twist-1 and
BMI-1 both act through negative regulation of p14ARF to inac-
tivate the p53 pathway, this could also be overcome by the use
4http://www.ptcbio.com/ptc596
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of MDM2-p53 antagonists. A study to evaluate the therapeutic
efficacy of PTC596 in neuroblastoma is warranted.
miRNA mimics and antagomirs
It has become increasingly evident that miRNAs play a role in
tumorigenesis and thus are potential targets for cancer therapy.
The widespread deregulation of miRNAs in neuroblastoma is
reported to be due to MYCN amplification and chromosomal
imbalances (Bray et al., 2009). Several miRNAs have been sug-
gested to have prognostic significance and therapeutic potential in
neuroblastoma including miR-34a and miR-380-5p (reviewed by
Verissimo et al., 2011). The restoration of miR-34a and inhibition
of miR-380-5p have been shown to reactivate the p53 pathway and
inhibit MYCN expression, as well as inhibiting tumor growth in
cell lines and orthotopic murine models of neuroblastoma (Wei
et al., 2008; Swarbrick et al., 2010; Tivnan et al., 2012). Advances in
miRNA cancer therapy toward clinical use are being made. MiR-
34 mimics developed by Mirna Therapuetics Inc., are anticipated
to enter clinical trials in early 2013 (Bader, 2012). Miravirsen, a
miRNA-targeted drug inhibiting miR-122, was the first of its class
to enter clinical trials and is currently in phase II trials for the
treatment of patients with Hepatitis C virus (Hu et al., 2012).
Other strategies
Similar to miR-34a, CHD5 is also located at 1p36, and is frequently
deleted and/or methylated in several human cancers including
neuroblastoma. 1p deletion and epigenetic silencing of CHD5 have
been suggested to account for the low expression observed in both
neuroblastoma tumors and cell lines, as homozygous deletions
or mutations were reported to be infrequent (Fujita et al., 2008;
Koyama et al., 2012). The promising therapeutic implications of
restoring CHD5 expression in neuroblastoma has previously been
shown by the reduced clonogenicity and xenograft tumor growth
of neuroblastoma cell lines stably transfected with CHD5 cDNA
(Fujita et al., 2008). Very recently, genistein has been reported
to demethylate the CHD5 promoter, enhance the expression of
CHD5 and p53, and inhibit neuroblastoma growth in vivo (Li
et al., 2012b).
Originally identified as genes downregulated by MYCN,
NDRG1, and NDRG2 have subsequently been shown to be neces-
sary for p53-mediated apoptosis. NDRG1 has been shown to be
upregulated in response to differentiation and suppress metas-
tasis, and there is growing interest in using NDRG1 as a bio-
marker of disease progression (reviewed by Ellen et al., 2008). Very
recently, NDRG1 has been shown to upregulate NEDD4L, PTEN,
and SMAD4 and inhibit the PI3K and Ras signaling pathways,
thereby implicating its involvement in regulating key oncogenic
pathways (Kovacevic et al., 2012). The exact role of NDRG1 and
family members in cancers including neuroblastoma remain to
be fully elucidated, however the iron chelator Dp44mT which
exhibits anti-cancer properties has been reported to upregulate
the expression of NDRG1 (Chen et al., 2012).
SKP2
S-phase kinase-associated protein 2 (SKP2) is an F-Box protein
and the variable substrate recognition component of the E3 ubiq-
uitin ligase SCFSKP2 complex. The invariable core components of
SCF complexes are SKP1, CUL1, and RBX1 (Skowyra et al., 1997;
Deshaies, 1999; Nakayama and Nakayama, 2005). SKP2 was orig-
inally discovered as a protein associated with Cyclin A-CDK2, and
subsequently shown to play a key role in promoting cell cycle pro-
gression, in particular at the G1/S transition (Zhang et al., 1995).
More recently, studies have also identified the involvement of SKP2
in several processes closely linked to tumorigenesis such as cell
survival, apoptosis, migration, and metastasis (reviewed by Chan
et al., 2010b).
SKP2 protein is approximately 45 kDa, consisting of an N-
terminal F-Box domain which mediates the interaction between
SKP2 and SKP1, thereby tethering SKP2 to the SCF complex,
and C-terminal leucine-rich repeats (LRR) which enable SKP2
to directly bind to target substrates (Bai et al., 1996; Skowyra
et al., 1997; Schulman et al., 2000; Zheng et al., 2002). Since its
discovery, SKP2 has been found to target numerous proteins for
ubiquitination and subsequent degradation via the 26S protea-
some pathway, including CDK inhibitors p21CIP1 (Yu et al., 1998;
Bornstein et al., 2003), p27KIP1 (Carrano et al., 1999; Sutterluty
et al., 1999; Tsvetkov et al., 1999), and p57KIP2 (Kamura et al.,
2003), Rb family member p130 (Tedesco et al., 2002), apoptosis
regulator FOXO1, tumor suppressors BRCA2 (Moro et al., 2006),
RASSF1A (Song et al., 2008), and TOB1 (Hiramatsu et al., 2006),
Cyclins D (Yu et al., 1998) and E (Yeh et al., 2001), as well as onco-
genes c-MYC (Kim et al., 2003; von der Lehr et al., 2003) and
MYB (Charrasse et al., 2000). The binding and recognition of the
substrate by SKP2 is dependent on prior phosphorylation of the
target substrate, and in some cases also requires the activity of a
co-factor protein, CKS1 (Cyclin-kinase-subunit 1; Ganoth et al.,
2001; Spruck et al., 2001; Frescas and Pagano, 2008).
REGULATION OF SKP2 EXPRESSION, STABILITY, AND ACTIVITY
Consistent with its role as a cell cycle regulator, expression lev-
els of SKP2 oscillate during the cell cycle, and are regulated by
both transcriptional and post-transcriptional mechanisms (Bashir
and Pagano, 2004). Levels of SKP2 are low in G0/G1 and late
M/early G1, increase during G1/S transition and reach a maxi-
mum in S phase (Wirbelauer et al., 2000; Bashir et al., 2004; Wei
et al., 2004). Studies to date have revealed that several transcrip-
tion factors act directly via the SKP2 promoter to upregulate SKP2
gene expression, such as E2F1 (Zhang and Wang, 2006), NFkB
(Schneider et al., 2006), SP1 (Appleman et al., 2006), CBF1 (Sar-
mento et al., 2005), GABP (Imaki et al., 2003), FOXM1 (Wang
et al., 2005), c-MYC (Bretones et al., 2011), STAT3 (Huang et al.,
2012), and NOR1 (Gizard et al., 2011). In addition, Foxp3 (Zuo
et al., 2007), FOXO3A (Wu et al., 2012b) and STAT1 (Wang
et al., 2010c) have been identified to transcriptionally repress SKP2
expression.
The identification of SKP2 as a direct target gene of E2F (Zhang
and Wang, 2006) is of particular importance as Yung et al. (2007)
subsequently described the SKP2 autoinduction loop compris-
ing pRB-E2F, SKP2, p27KIP1, and Cyclin E-CDK2, in which SKP2
expression initiates proteolysis of p27KIP1, activation of Cyclin E-
CDK2 which feeds back to sustain pRB inactivation, E2F release,
and further induction of the SKP2 gene. Therefore, once acti-
vated, this autoinduction loop ensures mitogen independent cell
cycle progression through the restriction point.
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In addition to transcriptional regulation, SKP2 is also sub-
ject to regulation via protein stability. The E3 ubiquitin ligase
APCCdh1 complex mediates the ubiquitination and subsequent
degradation of SKP2, primarily in early G1 (Bashir et al., 2004;
Wei et al., 2004). The interaction between Cdh1 and SKP2 is
essential for APCCdh1 complex mediated degradation of SKP2.
In support of this, several kinases including CDK2, AKT, and
Pim-1 have been shown to phosphorylate SKP2 at residues Ser-
64 and Ser-72 and/or Thr-417, thereby inhibiting the Cdh1-SKP2
interaction and protecting SKP2 from APCCdh1 mediated ubiq-
uitination and degradation. Furthermore, Pim-1 has also been
shown to phosphorylate Cdh1, impairing its association with
CDC27 and inhibiting APCCdh1 activity, thereby protecting SKP2
from degradation (reviewed by Chan et al., 2010b). In con-
trast, studies have shown that pRb interacts with Cdh1 and pro-
motes SKP2 degradation (Binne et al., 2007), and TGFβ signaling
induces nuclear translocation of SKP2 which facilitates its ubiq-
uitylation by APCCdh1 and subsequent degradation (Hu et al.,
2011).
Finally, the formation of the SCFSKP2 complex is critical for lig-
ase activity. Studies have demonstrated that PI3K/AKT signaling
pathway and Cyclin D positively regulate SCFSKP2 complex forma-
tion and ligase activity, potentially through neddylation of CUL1
(reviewed by Chan et al., 2010b).
SKP2 AS AN ONCOPROTEIN
Numerous studies to date have provided evidence showing the
oncogenic potential of SKP2, and its cross-talk with multiple sig-
naling pathways involved in carcinogenesis such as PI3K/AKT,
mTOR, ERK, NFkB, Ras/MAPK, and IGF (Wang et al., 2012c).
Overexpression of SKP2 can drive quiescent cells to enter the cell
cycle (Sutterluty et al., 1999), and promote adhesion-independent
growth of cancer cells (Carrano and Pagano, 2001; Signoretti et al.,
2002). Downregulation or inhibition of SKP2 expression leads to
growth arrest and/or apoptosis, as well as reduced cell migration,
invasion, and metastasis (Koga et al., 2003; Yokoi et al., 2003; Jiang
et al., 2005; Lee and McCormick, 2005; Shibahara et al., 2005; Kata-
giri et al., 2006; Kitagawa et al., 2008; Xiao et al., 2009; Chan et al.,
2010a; Bretones et al., 2011). In transgenic mouse models, SKP2
cooperates with N-Ras to drive lymphomagenesis (Latres et al.,
2001), and tissue targeted expression of SKP2 results in hyper-
plasia, dysplasia, and low-grade carcinoma of the prostate gland
(Shim et al., 2003). Knockdown of SKP2 significantly reduced
tumor formation and metastasis of breast cancer xenografts (Chan
et al., 2010a). Furthermore, work in SKP2 knockout mice demon-
strated that SKP2 is necessary for tumor formation induced by
PTEN, p19ARF, or Rb deficiency (Lin et al., 2010; Wang et al.,
2010b).
SKP2 overexpression at the mRNA and/or protein level have
been detected in a number of human tumors and cell lines
including prostate, breast, pancreatic, gastric, colorectal, ovarian,
melanoma, lymphoma, and leukemia (reviewed by Nakayama and
Nakayama, 2006; Frescas and Pagano, 2008; Hershko, 2008). In
addition, amplification of SKP2 at chromosome 5p13 has been
reported (Yokoi et al., 2004; Saigusa et al., 2005; Wang et al., 2009;
Rose et al., 2011; Li et al., 2012a), and tends to be observed in
metastatic tumors whereas overexpression of SKP2 is reported
in early cancers (Hershko, 2008). Overall, elevated SKP2 expres-
sion has been shown to correlate with a poor prognostic out-
come, tumor size, dedifferentiation, advanced grade, and metasta-
sis (reviewed by Wang et al., 2012c). It is worth mentioning that in
some cases the latter has been correlated with cytoplasmic and not
nuclear SKP2 expression. In the vast majority of cases, SKP2 over-
expression inversely correlates with p27KIP1 expression (Nakayama
and Nakayama, 2006; Frescas and Pagano, 2008), which is consis-
tent p27KIP1 being a key target of SKP2 and to be rarely mutated
in cancer (Chu et al., 2008). Finally, in recent years, SKP2 overex-
pression has been shown to mediate resistance to TRAIL induced
apoptosis (Schuler et al., 2011), and radio- and chemoresistance
of human cancer cells (Ishii et al., 2004; Davidovich et al., 2008;
Chan et al., 2012; Totary-Jain et al., 2012; Wang et al., 2012b).
SKP2 mediated attenuation of p53 function
Recent key publications have identified that SKP2 and an alterna-
tively spliced variant of SKP2, SKP2B can attenuate p53 function
through independent mechanisms (Figure 3). Initially, Kitagawa
et al. (2008) identified that SKP2 is able to suppress p53-mediated
apoptosis by inhibiting the p53 transcriptional co-activator, p300.
This function was shown to be independent of the F-Box motif
of SKP2 and hence SCFSKP2 complex function. SKP2 was found
to bind to the CH1 and CH3 domain of p300, thought to be
p53 binding sites, thereby antagonizing the p53-p300 interaction,
suppressing p300-mediated acetylation of p53 and the transacti-
vation ability of p53. In addition, secondary to the latter, SKP2 was
also observed to promote the degradation of p300. As proof-of-
concept, the study demonstrated that inhibition of SKP2 com-
bined with DNA damaging agents or Nutlin-3, led to greater
induction of apoptosis (Kitagawa et al., 2008). More recently,
SKP2B was demonstrated to attenuate p53 function via a mecha-
nism independent of p300. SKP2B is shown to bind to and mediate
the degradation of Prohibitin, a potential TSG which binds to
and stimulates p53 transcriptional activity. Taken together, these
observations suggest that amplification of the SKP2 locus would
represent a powerful mechanism to attenuate p53 function in
cancer (Chander et al., 2010; Figure 3).
Interestingly, a very recent study has reported an additional
mechanism for the SKP2-p300 interaction, whereby p300 is able
to reciprocally regulate SKP2 function (Figure 3). p300-mediated
acetylation of SKP2 at Lys-68 and Lys-71 within its NLS region
was shown to promote SKP2 stabilization and cytoplasmic reten-
tion, thereby influencing its oncogenic potential. In part the latter
was reported to be achieved through cytoplasmic SKP2 mediated
increased cellular migration via ubiquitination and destruction of
E-cadherin (Inuzuka et al., 2012).
THE ROLE OF SKP2 IN NEUROBLASTOMA
In line with observations that SKP2 drives cellular proliferation,
cAMP induces proliferation of neuroblastoma cells by upregulat-
ing SKP2 (Cho et al., 2007), while growth arrest and differentiation
of neuroblastoma cell lines induced by retinoic acid, BMP2, and
the HDAC inhibitor Helminthosporium carbonum toxin is accom-
panied by a decrease in SKP2 levels (Nakamura et al., 2003a,b;
Cuende et al., 2008; Deubzer et al., 2008a). This decrease has been
attributed to retinoic acid induced downregulation of Rae1 which
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FIGURE 3 | MYC proteins and SKP2. SKP2 is an oncoprotein which can be
upregulated by MYC proteins to drive tumorigenesis. SKP2 is a direct target
gene of c-MYC, and can regulate the stability of c-MYC and be a co-factor for
c-MYC mediated transcriptional activation of target genes. Due to the
homology between c-MYC and MYCN, it is possible that SKP2 is also a direct
target gene of MYCN and plays a similar role in regulating MYCN stability and
transactivation of MYCN target genes (as indicated by the dashed lines). In
neuroblastoma, MYCN can indirectly upregulate SKP2 via CDK4. In addition to
upregulation by oncogenic MYC proteins, several signaling pathways closely
linked to carcinogenesis such as PI3K/AKT and mTOR have been shown to
influence SKP2 expression, stability and SCFSKP2 ligase activity. SKP2 is a
component of the SCFSKP2 complex which mediates the degradation of
several substrates including CDK inhibitors p21CIP1, p27KIP1, and p57KIP2.
Independently of SCF complex formation, SKP2 can bind to p300 and
attenuate p53 function. Interestingly, p300 is able to reciprocally regulate
SKP2 activity. SKP2B, an alternatively spliced variant of SKP2, can perturb
both p53 and pRB pathways via degradation of Prohibitin. It is possible that
SKP2 has other functions which may promote tumorigenesis.
leads to increased APCCdh1 mediated degradation of SKP2, or
HDAC inhibitor induced activation of the Rb pathway (Cuende
et al., 2008; Deubzer et al., 2008b).
Several studies including our own have found higher expres-
sion of SKP2 in the presence of ectopic MYCN, and in MYCN
amplified cell lines and tumors (Sugihara et al., 2006; Bell et al.,
2007a; Westermann et al., 2007; Chen et al., 2010; Muth et al.,
2010; Table 2), suggesting that deregulated SKP2 expression is dri-
ven by MYCN to promote neuroblastoma. The exact role of SKP2
in neuroblastoma pathogenesis is currently unclear. It is possi-
ble that high expression of SKP2 simply collaborates with MYCN
to drive uncontrolled proliferation through increased degrada-
tion of CDK inhibitors. Alternatively, as Myc family members
are known to drive both proliferation and apoptosis, MYCN
may upregulate SKP2 to inhibit apoptosis and tip the balance
in favor of proliferation. In particular, as p53 has previously
been shown to be a direct target gene of MYCN, and a mech-
anism for MYCN mediated apoptosis in neuroblastoma, it is
plausible that MYCN directly upregulates SKP2 to attenuate
p53-mediated apoptosis (Kitagawa et al., 2008; Chen et al., 2010),
as has previously been reported for c-MYC (Bretones et al., 2011;
Figure 3).
The precise mechanism of MYCN mediated upregulation of
SKP2 remains unclear, as SKP2 is a direct target gene of E2F (Zhang
and Wang, 2006), E2F is a direct target of c-MYC (Fernandez et al.,
2003) and higher E2F expression levels are observed in the presence
of MYCN (Mac et al., 2000; Woo et al., 2008). In neuroblastoma
tumors, SKP2 expression has been shown to tightly correlate with
E2F1 expression, and both genes are expressed at significantly
higher levels in MYCN amplified tumors (Westermann et al., 2007;
Muth et al., 2010). Interestingly, although SKP2 expression levels
were found to be highest in MYCN amplified tumors, this did not
correlate with MYCN expression in MYCN single-copy tumors
(Westermann et al., 2007). Similarly, Bell et al. (2007a) reported
that although SKP2 mRNA levels decreased after MYCN siRNA
and after removal of MYCN expression in Tet21N cells, SKP2 pro-
tein levels did not correlate with MYCN protein levels or MYCN
amplification in a panel of neuroblastoma cell lines. It has been
www.frontiersin.org November 2012 | Volume 2 | Article 173 | 13
Chen and Tweddle p53, SKP2, and DKK3 in neuroblastoma
Table 2 | Summary of studies which have shown increased SKP2 expression in the presence of MYCN and/or MYCN amplification in
neuroblastoma.
Study Tumors Cell Lines Methods Evidence
Sugihara et al. (2006) – SHEP-MYCN1 WB E
Bell et al. (2007a) – IMR32, SKNBE2C, Tet21N2 MYCN siRNA, microarray3, qRT-PCR Si, E
Westermann et al. (2007) 49/117/141/19
Microarray/qRT-PCR/IHC
tissue array/WB
– Microarray, qRT-PCR, WB, IHC T
Chen et al. (2010) – Tet21N Microarray E
Muth et al. (2010) 251 Microarray SHEP, SHSY5Y, SKNSH, SKNBE2C, IMR32,
IMR5-75, Kelly, Tet21N, IMR5-75-shMYCN4
Microarray, SKP2 promoter assay,
MYCN shRNA, qRT-PCR, WB
T, R, Sh, E
1SHEP cells transfected with retroviral control vector or vector containing MYCN; 2GIMEN, NB69, LAN-6, NBL-S, PER-108, SMSKCNR, NBLW, CHLA-136, and NGP
were analyzed for SKP2 protein expression using WB, however no correlation between SKP2 protein expression and MYCN protein expression or MYCN amplification
was observed; 3Microarray analysis performed on IMR32 and SKNBE2C cells treated with scrambled or MYCN siRNA for 16 and 48 h; 4IMR5-75 cells with inducible
stably transfected short hairpin RNAs against MYCN.
WB, Western blotting; IHC, immunohistochemistry; R, reporter gene assays; Si, differential expression following MYCN siRNA; Sh, differential expression following
MYCN shRNA; E, differential expression/correlation in ectopic MYCN expression systems; T, correlation in tumors with MYCN amplification.
suggested that deregulated MYCN expression in MYCN amplified
neuroblastoma indirectly upregulates SKP2 via the induction of
CDK4 (Figure 3), thereby reducing the abundance of repressive
pRB-E2F1 complexes bound to the SKP2 promoter and provid-
ing an entry point into the SKP2 autoinduction loop (Muth et al.,
2010). Whether SKP2 is a direct transcriptional target of MYCN
remains to be determined. However, as c-MYC and MYCN are
known to share some common target genes, and c-MYC has
recently been shown to directly bind to two high affinity E-Box
motifs (CATGCG and CACGCG) mapping to−756 and−389 bp
upstream of the transcriptional start site within the SKP2 pro-
moter and drive transcription (Bretones et al., 2011), it is therefore
possible that MYCN may also directly regulate SKP2 expression
(Figure 3).
Whether or not SKP2 is a direct target gene of MYCN, the
prognostic significance of SKP2 overexpression in neuroblastoma
has been demonstrated in primary tumor samples. High SKP2
expression was found to characterize aggressive high-risk dis-
ease independent of both MYCN status and stage. Furthermore,
high SKP2 expression was observed to correlate with low p27KIP1
expression levels (Westermann et al., 2007), consistent with stud-
ies in other cancer types (reviewed by Nakayama and Nakayama,
2006; Frescas and Pagano, 2008; Hershko, 2008). Interestingly,
the prognostic value of low p27KIP1 expression in neuroblastoma,
independent of MYCN status had previously been demonstrated
(Bergmann et al., 2001).
SKP2 has previously been shown to regulate the stability of c-
MYC and to be a co-factor for c-MYC mediated transcriptional
activation of target genes (Kim et al., 2003; von der Lehr et al.,
2003), however it is currently remains unclear whether it plays a
similar role in regulating MYCN stability and transactivation of
MYCN target genes (Figure 3).
Taken together, SKP2 has prognostic significance in neuroblas-
toma and could be a promising novel therapeutic target, however
further studies investigating the role of SKP2 in neuroblastoma are
required. Consequently, together with in vitro experiments, cross-
ing SKP2 knockout mice with murine models of neuroblastoma,
such as the transgenic TH-MYCN mouse, the role of SKP2 in
driving neuroblastoma could be elucidated.
THERAPEUTIC STRATEGIES TARGETING SKP2
Over the past decade, SKP2 has emerged as a novel and attrac-
tive pharmacological target in cancer therapeutics. This is sup-
ported by the involvement of SKP2 in proliferation, apoptosis,
differentiation, migration, and metastasis, as well as its cross-talk
with multiple signaling pathways closely linked to carcinogene-
sis. In addition, the prognostic significance and overexpression of
SKP2 in a variety of human cancers, combined with observations
that SKP2 knockout mice are both viable and fertile (Nakayama
et al., 2000), further strengthens its appeal. Furthermore, with
the discovery of the role of SKP2 and SKP2B in attenuating p53-
mediated apoptosis and transcriptional activity, and that SKP2
deficiency triggers a potent ARF-p53-independent cellular senes-
cence in the presence of oncogenic conditions (such as inactivation
of TSGs/overexpression of proto-oncogenes), has implicated the
wide applicability of targeting SKP2 as a strategy to reactivate p53
and as pro-senescence therapy (Kitagawa et al., 2008; Chander
et al., 2010; Lin et al., 2010). Finally, the availability of crystal-
lographic maps of the structure of SKP2 and SCFSKP2 complex
components and their interaction with substrates, together with
biochemical data provides the opportunity to develop novel SKP2
inhibitors (Frescas and Pagano, 2008).
Inhibitors targeting the ubiquitin proteasome system (UPS)
have been developed and used with success in preclinical and/or
clinical studies thereby highlighting these inhibitors as a new class
of cancer therapeutics (Kisselev et al., 2012). Bortezomib (Vel-
cade™) is the first clinically approved proteasome inhibitor, and
has been reported to induce p27KIP1 expression through degrada-
tion of SKP2 (Uddin et al., 2008, 2009). Of interest, although not
directly linked to SKP2, bortezomib is shown to induce apoptosis
and inhibit cell growth, migration, angiogenesis, and metasta-
sis both in vitro and in murine models of chemosensitive and
chemoresistant neuroblastoma (Brignole et al., 2006; Michaelis
et al., 2006; Hamner et al., 2007; Valentiner et al., 2009). Despite
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the overall success of bortezomib, severe side-effects have been
reported in patients, and may be attributable to the broad ranging
functions and targets of the UPS (Chen et al., 2011). Therefore the
development of specific inhibitors directly targeting SKP2 is likely
to have enhanced efficacy and reduced toxicity.
To date, no specific inhibitor of SKP2 has been identified how-
ever three SMIs have been shown to downregulate SKP2 activity,
and exhibit anti-tumor effects in preclinical studies. Using high-
throughput screening, Cpd A and SMIP004 were identified (Chen
et al., 2008; Rico-Bautista et al., 2010). CpdA, interferes with the
SKP1/SKP2 interaction, thereby directly preventing SCFSKP2 com-
plex formation and ligase activity that results in the accumulation
of several SCFSKP2 substrates including p27KIP1 and p21CIP1. It has
been shown to induce cell cycle arrest and apoptosis, exhibiting
preferential activity against neoplastic cells, as well as overcoming
chemoresistance to dexamethasone, doxorubicin, melphalan, and
bortezomib (Chen et al., 2008). Similarly, SMIP0004 was identified
and shown to inhibit cell growth and induce apoptosis, and exhibit
cancer cell specificity. It was found not only to downregulate SKP2
and induce dose-dependent stabilization of p27KIP1 and p21CIP1,
but also to inhibit cellular CDK2 activity (Rico-Bautista et al.,
2010). Finally, MLN4924 is a compound which targets NEDD8-
activating enzyme, consequently affecting CUL1 neddylation and
impairing SCFSKP2 complex formation and ligase activity. Pre-
clinically, MLN4924 exhibits potent cytotoxicity against a panel of
human cancer cell lines, and suppresses tumor growth in mouse
xenograft models (Soucy et al., 2009; Lin et al., 2010). Furthermore,
in contrast to bortezomib, MLN4924 did not significantly affect
bulk protein turnover (Soucy et al., 2009). MLN4924 was recently
evaluated by the Pediatric Preclinical Testing Program (PPTP),
exhibiting potent activity in vitro and inhibiting tumor growth
against a subset of the PPTP solid tumor and ALL xenografts.
Specifically in the neuroblastoma panel, MLN4924 had a median
relative IC50 of 278nM, and induced intermediate activity (EFS
T/C values>2) in 1/4 xenografts (Smith et al., 2012). In addition to
the above SMIs, several natural compounds have also been shown
to downregulate SKP2 activity, including retinoic acid, silibinin,
curcumin, quercetin, lycopene, epigallocatechin-3-gallate (Naka-
mura et al., 2003a; Roy et al., 2007; Cuende et al., 2008; Huang
et al., 2011a). Retinoic acid is of particular relevance to neuroblas-
toma, as Isotretinoin (13-cis RA) is routinely used in the treatment
of high-risk disease following high-dose chemotherapy and stem
cell rescue, in a setting of minimal residual disease (Wagner and
Danks, 2009).
Several signaling pathways have been shown to influence SKP2
expression, stability, and SCFSKP2 ligase activity, therefore an alter-
native strategy would be to use inhibitors that target components
of these pathways such as PI3K/AKT, mTOR, ERK, IGF, Notch,
and IKK/NFkB, and some of which are currently in clinical tri-
als. In support of this, PI3K inhibitor LY294002 and Rapamycin
have been shown to decrease SKP2 expression (Motti et al., 2005;
Shapira et al., 2006). Of interest, it is worth mentioning that
LY294002 has also been shown to destabilize MYCN in neurob-
lastoma (Chesler et al., 2006). Targeting the expression or stability
of SKP2 is an appealing option due to the oncogenic functions
of SKP2 which are independent of SCFSKP2 ligase formation and
activity (Ji et al., 2006; Kitagawa et al., 2008; Chan et al., 2010a).
DKK3
The Wnt signaling pathway is involved in embryogenesis, playing
a key role in both early and late cell-fate decisions, and also in
adult tissue homeostasis. Deregulated activation of this pathway
has been implicated in several malignancies (Klaus and Birch-
meier, 2008). DKK3 is a member of the Dickkopf family of secreted
Wnt antagonists, which also includes DKK1,−2,−4 and DKKL1.
DKK family members encode glycoproteins which all share an N-
terminal signal peptide, and with the exception of DKKL1, also
share two cysteine-rich domains termed Cys1 and Cys2 that are
separated by a non-conserved linker region of variable length.
DKK3 has a molecular weight of 38 kDa, and Cys1 and Cys2 are
separated by a linker region of 13 amino acids (reviewed by Veeck
and Dahl, 2012).
DKK1, −2 and −4, are well-established antagonists of the
canonical Wnt/β-catenin pathway through direct high affinity
binding to Wnt co-receptors lipoprotein receptor-related protein 5
and 6 (LRP5/6), and also DKK receptors Kremen 1 and 2 (KRM1/2;
reviewed by (Niehrs, 2006)). The co-binding of DKK proteins
to KRM1/2 receptors potentiates the ability of DKK proteins to
inhibit Wnt signaling, through the formation of a ternary complex
that leads to endocytosis and degradation of LRP receptors (Mao
et al., 2002; Mao and Niehrs, 2003). In contrast, the role of DKK3 as
a Wnt inhibitor is less clear. In some studies, DKK3 is not shown to
bind to LRP5/6 at the cell surface membrane, and whether it binds
to KRM1/2 remains controversial (Mao et al., 2002; Nakamura
and Hackam, 2010). In contrast, others have however confirmed
DKK3 as an inhibitor of the canonical pathway (Yue et al., 2008;
Lee et al., 2009; Dellinger et al., 2012).
DKK3 AS A TUMOR SUPPRESSOR
Several lines of evidence exist to suggest that DKK3 acts as a tumor
suppressor. Originally identified as a novel TSG by Tsuji et al.
(2000) using an in vitro transformation model of normal human
fibroblasts, reduced DKK3 expression was subsequently observed
in cell lines and tumors of several different cancer types includ-
ing liver, lung, prostate, breast, osteosarcoma, and leukemia (Tsuji
et al., 2000; Nozaki et al., 2001; Hsieh et al., 2004; Kurose et al., 2004;
Roman-Gomez et al., 2004; Abarzua et al., 2005; Tanimoto et al.,
2007; Mizobuchi et al., 2008; Veeck et al., 2008; Yue et al., 2008; Yu
et al., 2009; Dellinger et al., 2012). Studies into the mechanisms
behind reduced DKK3 expression have revealed histone modifi-
cation in cancers such as renal cell carcinoma (Ueno et al., 2011),
and hypermethylation of the DKK3 promoter in a vast number
of human cancers including lung, bladder, breast, and leukemia
(reviewed by Veeck and Dahl, 2012). Additionally, loss of heterozy-
gousity and homozygous deletions of the DKK3 gene at 11p15
have also been reported (Tsuji et al., 2001; Bashyam et al., 2005).
In some cases, reduced DKK3 expression and/or DKK3 promoter
methylation has been shown to be associated with poor prognos-
tic clinicopathologic characteristics and outcome (Roman-Gomez
et al., 2004; Yue et al., 2008; Veeck et al., 2009; Yu et al., 2009; Yang
et al., 2010; Dellinger et al., 2012; Wang et al., 2012a).
Overexpression of DKK3 has been shown to mediate potent
anti-tumor effects including reduced cell proliferation, anchorage-
independent growth, and invasion and metastasis, and induced
cancer cell specific apoptosis both in vitro and in murine tumor
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models (Tsuji et al., 2001; Abarzua et al., 2005; Edamura et al., 2007;
Tanimoto et al., 2007; Koppen et al., 2008; Mizobuchi et al., 2008;
Kawasaki et al., 2009; Gu et al., 2011; Than et al., 2011; Ueno et al.,
2011; Dellinger et al., 2012; Yang et al., 2012). The precise mecha-
nisms by which DKK3 inhibits tumorigenesis are not completely
understood. Studies using a replication incompetent adenoviral
vector incorporating the human DKK3 cDNA (Ad-REIC/DKK3)
have demonstrated that DKK3 induced apoptosis is mediated
via ER stress triggered activation of JNK with subsequent reduc-
tion in anti-apoptotic BCL2, mitochondrial translocation of BAX,
cytochrome C release, and activated caspase cleavage (Abarzua
et al., 2005, 2007; Tanimoto et al., 2007; Kashiwakura et al., 2008;
Kobayashi et al., 2008; Kawasaki et al., 2009). Ad-REIC/DKK3
has also been shown to induce an indirect host-mediated anti-
tumor effect via the induction of IL-7 (Sakaguchi et al., 2009). It
is however important to mention that mechanisms which mediate
resistance to DKK3 induced apoptosis have been identified, such
as the overexpression of heat shock protein 70/72, an ER-residing
chaperone BiP/GRP78 BiP/GRP78 and BCL2 (Veeck and Dahl,
2012). Interestingly, despite the vast body of evidence suggesting a
fundamental role for DKK3 in cancer development, DKK3 knock-
out mice were both viable and fertile and were not observed to
be more susceptible to cancer development (Barrantes Idel et al.,
2006).
THE ROLE OF DKK3 IN NEUROBLASTOMA
DKK3 is secreted in neuroblastoma cell lines, and in primary
tumors is found to be expressed in the endothelium (Koppen et al.,
2008; Haug et al., 2011). An initial study of DKK3 and neuroblas-
tic tumors observed that DKK3 expression was a marker of tumor
differentiation, where the highest expression was observed in the
most differentiated ganglioneuromas, and the lowest expression in
the least differentiated neuroblastoma. Specifically in neuroblas-
toma tumors, low DKK3 expression correlated significantly with
poor prognosis, however this was not independent of MYCN
amplification (Koppen et al., 2008). In a more recent study of
101 neuroblastic tumors including 88 neuroblastoma tumors, both
high DKK3 and DKK2 expression correlated with good prognosis
(Revet et al., 2010).
Several studies to date including our own have observed an
inverse relationship between DKK3 expression and MYCN ampli-
fication and/or expression in both cell lines and primary tumors,
thereby suggesting that downregulation of DKK3 is necessary for
progression of MYCN amplified neuroblastoma (Table 3; Bell
et al., 2007a; Koppen et al., 2008; Chen et al., 2010; Haug et al., 2011;
De Brouwer et al., 2012; Figure 4). Consistent with this, overex-
pression of DKK3 inhibited the proliferation of MYCN amplified
neuroblastoma cell lines in vitro (Koppen et al., 2008).
To determine the mechanism responsible for low DKK3 expres-
sion in MYCN amplified tumors, studies have observed that
irrespective of MYCN status, reduced DKK3 expression in neurob-
lastoma was not due to promoter hypermethylation (Haug et al.,
2011). Through ChIP analysis, MYCN was reported to downregu-
late DKK3 expression through a mechanism independent of direct
transcriptional repression (Koppen et al.,2008). Indeed, in support
of this, two recent independent studies have shown that MYCN
regulates the expression and secretion of DKK3 in neuroblastoma
cells through direct upregulation of the oncogenic miR-17-92 clus-
ter (e.g., miR-92a, -92b, and -19b) which target the 3′UTR of DKK3
(Haug et al., 2011; De Brouwer et al., 2012; Figure 4). Analysis
of primary tumors demonstrated a positive correlation between
MYCN expression and miR-17-92 cluster expression, consistent
with previous studies (Schulte et al., 2008), and an inverse corre-
lation between miR-17-92 cluster expression and DKK3 expres-
sion (Haug et al., 2011; De Brouwer et al., 2012). In line with
higher DKK3 expression in ganglioneuroma and ganglioneurob-
lastoma, these tumors had lower levels of miR-92a compared with
neuroblastoma (Haug et al., 2011).
The precise mechanism by which DKK3 suppresses neurob-
lastoma tumorigenesis is unclear however this does not appear
to be through inhibition of the canonical Wnt/β-catenin signal-
ing pathway (Koppen et al., 2008). It is possible that DKK3 may
act by inhibiting non-canonical Wnt signaling pathways such as
the Planar cell polarity (PCP)-pathway, or the Wnt/Ca2+ pathway.
Table 3 | Summary of studies which have observed an inverse relationship between DKK3 expression and MYCN expression and/or MYCN
amplification in neuroblastoma.
Study Tumors Cell Lines Methods Evidence
Bell et al. (2007a) – IMR32, SKNBE2C and Tet21N MYCN siRNA, Microarray1, qRT-PCR Si, E
Koppen et al. (2008) 13 Ganglioneuroma, 14
ganglioneuroblastoma,
82 neuroblastoma
14 MNA and 8 MYCN single-copy NB cell
lines2, Tet21N, SKNAS-NMYCER
Microarray3, Northern blot T, C, E
Chen et al. (2010) – Tet21N Microarray E
Haug et al. (2011) 25 Neuroblastoma SKNBE2C, Kelly, Tet21N IHC, shMYCN, qRT-PCR T, Sh, E
De Brouwer et al. (2012) 101 Neuroblastoma 7 MNA and 5 MYCN single-copy NB cell
lines2, Tet21N
qRT-PCR T, C, E
1Microarray analysis performed on IMR32 and SKNBE2C cells treated with scrambled or MYCN siRNA for 16 and 48 h; 2see publication for full list of cell lines used;
3performed on 12/22 neuroblastoma cell lines.
MNA; MYCN amplified; NB, neuroblastoma; IHC, immunohistochemistry; Si, differential expression following MYCN siRNA; Sh, differential expression following
MYCN shRNA; E, differential expression/correlation in ectopic MYCN expression systems;T, differential expression/correlation in tumors with MYCN amplification; C,
differential expression/correlation in cell lines with/without MYCN amplification.
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FIGURE 4 | MYCN mediated downregulation of DKK proteins in
neuroblastoma. DKK1 and DKK3 can inhibit the proliferation of
neuroblastoma cells, therefore downregulation of DKK proteins by MYCN
will favor neuroblastoma tumorigenesis. MYCN mediated downregulation
of DKK3 can occur via upregulation of the oncogenic miR-17-92 cluster, and
due to the homology between DKK family members, this may also be a
potential mechanism for MYCN mediated downregulation of DKK1 (as
indicated by the dashed line). DKK1 inhibits the proliferation of
neuroblastoma cells via upregulation of SYNPO2, and although the
mechanism for DKK3 remains unclear, due to the homology between DKK
family members this may also occur via SYNPO2 (as indicated by the
dashed line).
Interestingly, these non-canonical Wnt pathways have previously
been shown to control neural crest migration (De Calisto et al.,
2005).
Similar to DKK3, DKK1 is also reported to be secreted in neu-
roblastoma cell lines, and downregulated indirectly by MYCN
(Koppen et al., 2007). Lower expression was observed in the pres-
ence of ectopic MYCN and in MYCN amplified tumors (Bell et al.,
2007b; Koppen et al., 2007; Chen et al., 2010). Overexpression
of DKK1 inhibited the proliferation of neuroblastoma cell lines
through upregulation of synaptopodin-2 (SYNPO2), a protein
previously reported to suppress tumor growth, and not by inhi-
bition of canonical Wnt/β-catenin signaling (Koppen et al., 2007;
Figure 4).
The above findings suggest that DKK proteins may play a role
in neuroblastoma pathogenesis, therefore it would be interesting
to assess tumor formation in TH-MYCN transgenic mice defi-
cient in DKK3 or DKK1. Certainly, the Wnt pathway is involved
in early formation of the neural crest and the subsequent develop-
ment, migration, and terminal differentiation of neural crest cells
(Barembaum and Bronner-Fraser, 2005; Ille and Sommer, 2005),
and Wnt/β-catenin signaling has been shown to directly induce
MYCN expression (Kuwahara et al., 2010). Additionally, embry-
onal malignancies of childhood such as neuroblastoma have been
suggested to be disorders of normal development (reviewed by
Grimmer and Weiss, 2006; Johnsen et al., 2009), therefore it is
not surprising that deregulated Wnt pathway signaling may be
involved in neuroblastoma development.
To date, studies into Wnt signaling in neuroblastoma have
shown that siRNA mediated inhibition of the Wnt1/β-catenin
pathway leads to apoptosis of SHSY5Y cells (Zhang et al., 2009),
and deregulated canonical and non-canonical Wnt signaling in
chemoresistant and high-risk disease (Blanc et al., 2005; Liu et al.,
2008b; Flahaut et al., 2009). Additionally, the expression of FZD6
is reported to predict poor survival in neuroblastoma patients,
and marks rare and highly tumorigenic neuroblastoma stem
cells (Cantilena et al., 2011). Furthermore, microarray analysis
of Tet21N MYCN+ and MYCN− cells identified that in addition
to DKK1 and DKK3, there was deregulated expression of several
components of the Wnt pathway in the presence of MYCN. These
included downregulation of additional Wnt signaling antagonists
SFRP1 and APC together with the upregulated expression of posi-
tive regulators FRAT2, CSNK2A1, and RUVBL1 (Chen, 2009; Chen
et al., 2010). Interestingly, in an independent study, SFRP1 was
observed to correlate with good prognosis in neuroblastic tumors
(Revet et al., 2010). CSNK2A1 and RUVBL1 have been reported to
play multiple roles in driving malignant transformation (Duncan
and Litchfield, 2008; Huber et al., 2008), and RUVBL1 expres-
sion was identified to be associated with poor overall survival in
neuroblastoma patients (Westermann et al., 2008). Finally, several
upstream components of the Wnt pathway have been reported to
be highly expressed in neuroblastic tumors and cell lines (Revet
et al., 2010). Taken together, these findings provide support to
suggest that the Wnt pathway may be important in neuroblas-
toma pathogenesis although the precise role remains unclear and
will require further investigation.
THERAPEUTIC STRATEGIES TO RE-ESTABLISH DKK3
Developmental pathways are becoming important targets for can-
cer therapy, and inhibitors targeting Wnt, Notch, and Hedgehog
have reached clinical evaluation (see footnote 3). The low expres-
sion of DKK3 in several human cancers combined with its cancer
specific apoptosis inducing effects suggest that re-establishing
DKK3 holds promise as a novel targeted cancer therapy. The use
of demethylating agents to re-express DKK3 in cancers where
promoter hypermethylation leads to gene silencing have been
shown in studies using cell lines of several cancers including gas-
tric, prostate, lung, and leukemia (reviewed by Veeck and Dahl,
2012). Demethylating agents azacitidine and decitabine have been
approved in the treatment of myelodysplastic syndromes (Cataldo
et al., 2009; Santos et al., 2010), however this method is not
gene specific and could alter the epigenetic patterns of the entire
genome. In neuroblastoma, demethylating agents are unlikely to
be of therapeutic use, as low DKK3 expression was not shown to
be due to promoter methylation (Haug et al., 2011). An alter-
native strategy involves DKK3 targeted gene therapy. The vast
majority of work to date has been carried out Ad-REIC/DKK3
(Abarzua et al., 2005), however the use of a biodegradable cationic
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polymer based vector has also been reported (Veeck and Dahl,
2012). Ad-REIC/DKK3 has been used with success in preclinical
studies demonstrating robust anti-tumor effects including induc-
tion of cancer cell specific apoptosis and inhibition of metastatic
disease (Abarzua et al., 2005; Edamura et al., 2007; Kawasaki
et al., 2009; Sakaguchi et al., 2009; Than et al., 2011), and is cur-
rently in clinical trials for use in prostate cancer (see footnote 3;
NCT01197209). In addition, DKK3 also appears to play a role in
chemoresistance, and Ad-REIC/DKK3 mediated downregulation
of MDR-1 expression through JNK activation sensitized previously
chemoresistant tumor cells to chemotherapy, which supports the
applicability of using Ad-REIC/DKK3 in combination with con-
vention chemotherapies in the treatment of drug-resistant cancers
(Kawasaki et al., 2009; Hirata et al., 2012). Preclinical studies to
evaluate the effect of Ad-REIC/DKK3 in neuroblastoma are yet to
be conducted.
Alternative strategies more specific to neuroblastoma may
involve the direct targeting of the oncogenic miR-17-92 cluster to
re-establish DKK3 expression in MYCN amplified neuroblastoma,
or the use of agents which directly affect MYCN expression in neu-
roblastoma cells such as the BET inhibitor, JQ1 (Mertz et al., 2011).
Certainly, targeting miRNAs as a new class of therapeutics has been
gaining increased interest in recent years, and Miravirsen, which
inhibits miR-122 is currently in phase II trials for the treatment of
patients with Hepatitis C virus (Hu et al., 2012).
CONCLUSIONS AND PERSPECTIVES
In recent years, the involvement of the p53/MDM2/p14ARF path-
way in neuroblastoma has become increasingly evident and target-
ing this pathway through small molecule inhibitors of the MDM2-
p53 interaction in neuroblastoma which remains predominantly
wt even at relapse, is an attractive therapeutic option. Cur-
rently newer more potent MDM2-p53 antagonists are undergoing
commercial development, which will be tested in suitable pre-
clinical models of neuroblastoma leading to their evaluation in
early phase clinical trials and hopefully eventually into standard
neuroblastoma therapy.
The precise involvement of SKP2 and DKK3 in neuroblastoma
will require further investigation and these targets are currently
much less developed in terms of their therapeutic potential. Nev-
ertheless their involvement in other cancers as well as neuroblas-
toma makes them a priority for commercial and academic drug
development programs.
It is envisaged that the therapeutic strategies which have been
proposed in this review are most likely to be effective in combi-
nation with existing treatment regimens or other targeted agents
and not alone. The increased understanding of neuroblastoma
tumorigenesis and mechanisms of therapy resistance and relapse,
advances in the development of murine models which more closely
resemble high-risk metastatic and/or relapsed disease, and the
drive towards targeted/personalized therapies, will hopefully pro-
vide increased opportunities to test out some of the paradigms
mentioned in this review. When testing therapies directed against
all these targets it will be important to do so both in MYCN ampli-
fied and non-amplified settings to fully evaluate their dependence
on MYCN.
This is an exciting time for neuroblastoma drug development
and with many new targeted agents in the pipeline undergoing
preclinical evaluation and early phase clinical trials it surely will
not be long before one reaches frontline therapy and improves the
outcome, whilst hopefully reducing long-term toxicity in patients
with high-risk disease.
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